

COMBINATION THERAPY FOR THE TREATMENT OF DIABETES

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U. S. Provisional Application 61/223,881,
5 filed on July 8, 2009, which is incorporated by reference herein in its entirety.

FIELD OF THE INVENTION

The present invention is directed to co-therapy and methods for the
treatment and prevention of glucose-related disorders such as Type 2 diabetes
10 mellitus and Syndrome X. The present invention is further directed to
pharmaceutical compositions for the co-therapy and methods described herein.

BACKGROUND OF THE INVENTION

Diabetes mellitus is a medical term for the presence of elevated blood
15 glucose. People with diabetes either don't produce insulin, produce too little
insulin or do not respond to insulin, resulting in the build up of glucose in the
blood. The most common form of diabetes is Type 2 diabetes, once referred to
as adult onset diabetes or non-insulin dependent diabetes (NIDDM), which may
account for >90% of diabetes in adults. However, as the younger population
20 becomes increasingly overweight or obese, Type 2 diabetes is becoming more
prevalent in teens and children. Diabetes may also refer to gestational
diabetes, Type 1 diabetes or autoimmune diabetes, once referred to as juvenile
onset diabetes and type 1 1/2 diabetes, also referred to as latent-autoimmune
diabetes in adults or LADA. Diabetes may occur because of poor dietary habits
25 or lack of physical activity (e.g., sedentary lifestyle), genetic mutations, injury to
the pancreas, drug (e.g., AIDS therapies) or chemical (e.g., steroid) exposure
or disease (e.g., cystic fibrosis, Down syndrome, Cushing's syndrome). Two
rare types of genetic defects leading to diabetes are termed maturity-onset
diabetes of the young (MODY) and atypical diabetes mellitus (ADM).

30 Type 2 diabetes mellitus (non-insulin-dependent diabetes mellitus or
NIDDM) is a metabolic disorder involving dysregulation of glucose metabolism
and insulin resistance, and long-term complications involving the eyes, kidneys,
nerves, and blood vessels. Type 2 diabetes mellitus usually develops in

adulthood (middle life or later) and is described as the body's inability to make either sufficient insulin (abnormal insulin secretion) or its inability to effectively use insulin (resistance to insulin action in target organs and tissues). More particularly, patients suffering from Type 2 diabetes mellitus have a relative
5 insulin deficiency. That is, in these patients, plasma insulin levels are normal to high in absolute terms, although they are lower than predicted for the level of plasma glucose that is present.

Type 2 diabetes mellitus is characterized by the following clinical signs or symptoms: persistently elevated plasma glucose concentration or
10 hyperglycemia; polyuria; polydipsia and / or polyphagia; chronic microvascular complications such as retinopathy, nephropathy and neuropathy; and macrovascular complications such as hyperlipidemia and hypertension which can lead to blindness, end-stage renal disease, limb amputation and myocardial infarction.

15 Syndrome X, also termed Insulin Resistance Syndrome (IRS), Metabolic Syndrome, or Metabolic Syndrome X, is a disorder that presents risk factors for the development of Type 2 diabetes mellitus and cardiovascular disease including glucose intolerance, hyperinsulinemia and insulin resistance, hypertriglyceridemia, hypertension and obesity.

20 The diagnosis of Type 2 diabetes mellitus includes assessment of symptoms and measurement of glucose in the urine and blood. Blood glucose level determination is necessary for an accurate diagnosis. More specifically, fasting blood glucose level determination is a standard approach used. However, the oral glucose tolerance test (OGTT) is considered to be more
25 sensitive than fasted blood glucose level. Type 2 diabetes mellitus is associated with impaired oral glucose tolerance (OGT). The OGTT thus can aid in the diagnosis of Type 2 diabetes mellitus, although generally not necessary for the diagnosis of diabetes (Emancipator K, Am J Clin Pathol 1999 Nov; 112(5):665-74; Type 2 Diabetes Mellitus, Decision Resources Inc., March
30 2000). The OGTT allows for an estimation of pancreatic beta-cell secretory function and insulin sensitivity, which helps in the diagnosis of Type 2 diabetes mellitus and evaluation of the severity or progression of the disease (e.g., Caumo A, Bergman RN, Cobelli C, J Clin Endocrinol Metab 2000, 85(11):

4396-402). More particularly, the OGTT is extremely helpful in establishing the degree of hyperglycemia in patients with multiple borderline fasting blood glucose levels that have not been diagnosed as diabetics. In addition, the OGTT is useful in testing patients with symptoms of Type 2 diabetes mellitus where the possible diagnosis of abnormal carbohydrate metabolism has to be clearly established or refuted.

Thus, impaired glucose tolerance is diagnosed in individuals that have fasting blood glucose levels less than those required for a diagnosis of Type 2 diabetes mellitus, but have a plasma glucose response during the OGTT between normal and diabetics. Impaired glucose tolerance is considered a pre-diabetic condition, and impaired glucose tolerance (as defined by the OGTT) is a strong predictor for the development of Type 2 diabetes mellitus (Haffner SM, Diabet Med 1997 Aug; 14 Suppl 3:S12-8).

Type 2 diabetes mellitus is a progressive disease associated with the reduction of pancreatic function and/or other insulin-related processes, aggravated by increased plasma glucose levels. Thus, Type 2 diabetes mellitus usually has a prolonged pre-diabetic phase and various pathophysiological mechanisms can lead to pathological hyperglycemia and impaired glucose tolerance, for instance, abnormalities in glucose utilization and effectiveness, insulin action and/or insulin production in the prediabetic state (Goldberg RB, Med Clin North Am 1998 Jul; 82(4):805-21).

The pre-diabetic state associated with glucose intolerance can also be associated with a predisposition to abdominal obesity, insulin resistance, hyperlipidemia, and high blood pressure, that is, Syndrome X (Groop L, Forsblom C, Lehtovirta M, Am J Hypertens 1997 Sep;10(9 Pt 2):172S-180S; Haffner SM, J Diabetes Complications 1997 Mar-Apr;11(2):69-76; Beck-Nielsen H, Henriksen JE, Alford F, Hother-Nielson O, Diabet Med 1996 Sep;13(9 Suppl 6):S78-84).

Thus, defective carbohydrate metabolism is pivotal to the pathogenesis of Type 2 diabetes mellitus and impaired glucose tolerance (Dinneen SF, Diabet Med 1997 Aug; 14 Suppl 3:S19-24). In fact, a continuum from impaired glucose tolerance and impaired fasting glucose to definitive Type 2 diabetes

mellitus exists (Ramlo-Halsted BA, Edelman SV, Prim Care 1999 Dec; 26(4):771-89).

Early intervention in individuals at risk to develop Type 2 diabetes mellitus, focusing on reducing the pathological hyperglycemia or impaired glucose tolerance may prevent or delay the progression towards Type 2 diabetes mellitus and associated complications and/or Syndrome X. Therefore, by effectively treating impaired oral glucose tolerance and / or elevated blood glucose levels, one can prevent or inhibit the progression of the disorder to Type 2 diabetes mellitus or Syndrome X.

Typical treatment of glucose disorders including Type 2 diabetes mellitus and Syndrome X focuses on maintaining the blood glucose level as near to normal as possible and includes diet and exercise, and when necessary, treatment with anti-diabetic agents, insulin or a combination thereof. Type 2 diabetes mellitus that cannot be controlled by dietary management is treated with oral antidiabetic agents including, but not limited to, sulfonylureas (e.g., not limited to first generation: chlorpropamide, tolazamide, tolbutamide; second generation: glyburide, glipizide; and third generation: glimepiride), biguanides (e.g., metformin), thiazolidinediones (e.g., rosiglitazone, pioglitazone, troglitazone), alpha-glucosidase inhibitors (e.g., acarbose, miglitol), meglitinides (e.g., repaglinide), other insulin-sensitizing compounds, and /or other anti-obesity agents (e.g., orlistat or sibutramine). For Syndrome X, the anti-diabetic agents are additionally combined with pharmacological agents for the treatment of the concomitant co-morbidities (e.g., antihypertensives for hypertension, hypolipidemic agents for hyperlipidemia).

First-line therapies typically include metformin and sulfonylureas as well as thiazolidinediones. Metformin monotherapy is a first line choice, particularly for treating Type 2 diabetic patients who are also obese and / or dyslipidemic. Lack of an appropriate response to metformin is often followed by treatment with metformin in combination with sulfonylureas, thiazolidinediones, or insulin.

Sulfonylurea monotherapy (including all generations of drugs) is also a common first line option. Another first line therapy choice may be thiazolidinediones. Patients who do not respond appropriately to oral anti-diabetic monotherapy, are given combinations of these agents. When glycemic

control cannot be maintained with oral antidiabetics alone, insulin therapy is used either as a monotherapy, or in combination with oral antidiabetic agents. These same strategies, optionally in combination with additional strategies (e.g., anti-hypertensive) can be used for the treatment of Syndrome X.

5 Anti-diabetic agents include, but are not limited to:

 (a) Sulfonylureas, which increase insulin production by stimulating pancreatic beta cells, and therefore act as insulin secretagogues. The primary mechanism of action of sulfonylureas is to close ATP-sensitive potassium channels in the beta-cell plasma membrane, initiating a chain of events that
10 result in insulin release. Suitable examples of sulfonylureas include, but are not limited to chlorpropamide, tolazamide, tolbutamide, glyburide, glipizide, glimepiride, and like.

 (b) Meglitinides, another class of insulin secretagogues, that have a mechanism of action distinct from that of the sulfonylureas. Suitable examples
15 of meglitinides include, but are not limited to repaglinide.

 (c) Agents which modify insulin secretion such as Glucagon-like Peptide-1 (GLP-1) and it's mimetics, Glucose-insulinotropic peptide (GIP) and it's mimetics, Exendin and it's mimetics, and Dipeptyl Protease Inhibitors (DPPIV).

 (d) Biguanides which decrease liver glucose production and increase the
20 uptake of glucose. Suitable examples include, but are not limited to metformin.

 (e) Thiazolidinediones, insulin sensitizing drugs which decrease peripheral insulin resistance by enhancing the effects of insulin at target organs and tissues. These drugs bind and activate the nuclear receptor, peroxisome proliferator-activated receptor-gamma (PPAR-gamma) which increases
25 transcription of specific insulin-responsive genes. Suitable examples of PPAR-gamma agonists are the thiazolidinediones which include, but are not limited to rosiglitazone, pioglitazone, troglitazone, isaglitazone (known as MCC-555), 2-[2-[(2R)-4-hexyl-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]ethoxy]-benzene acetic acid, and the like. Additionally, the non-thiazolidinediones also act as
30 insulin sensitizing drugs, and include, but are not limited to GW2570, and the like.

 (f) Retinoid-X receptor (RXR) modulators, also insulin sensitizing drugs, which include, but are not limited to targretin, 9-cis-retinoic acid, and the like.

(g) Other insulin sensitizing agents include, but are not limited to INS-1, PTP-1B inhibitors, GSK3 inhibitors, glycogen phosphorylase a inhibitors, fructose-1,6-bisphosphatase inhibitors, and the like.

(h) Alpha-glucosidase inhibitors which act to inhibit alpha-glucosidase.

- 5 Alpha-glucosidase converts fructose to glucose, thus these inhibitors delay the digestion of carbohydrates. The undigested carbohydrates are subsequently broken down in the gut, thereby reducing the post-prandial glucose peak. Suitable examples include, but are not limited to, acarbose and miglitol.

- (i) Insulins, including regular or short-acting, intermediate-acting, and
10 long-acting insulins, inhaled insulin and insulin analogues such as insulin molecules with minor differences in the natural amino acid sequence. These modified insulins may have faster onset of action and / or shorter duration of action.

- (j) Small molecule mimics of insulin, including, but not limited to L-
15 783281, TE-17411, and the like.

(k) Na-glucose co-transporter inhibitors which inhibit the renal reabsorption of glucose such as T-1095, T-1095A, phlorizin, and the like.

(l) Amylin agonists which include, but are not limited to pramlintide, and the like.

- 20 (k) Glucagon antagonists such as AY-279955, and the like.


- In addition to antidiabetic agents, therapies may include add-on treatment with anti-obesity agents such as orlistat, a pancreatic lipase inhibitor, which prevents the breakdown and absorption of fat; or sibutramine, an appetite suppressant and inhibitor of the reuptake of serotonin, norepinephrine
25 and dopamine in the brain. Other potential add-on anti-obesity agents include, but are not limited to, appetite-suppressants acting through adrenergic mechanisms such as benzphetamine, phenmetrazine, phentermine, diethylpropion, mazindol, sibutramine, phenylpropanolamine or, ephedrine; appetite-suppressant agents acting through serotonergic mechanisms such as
30 quipazine, fluoxetine, sertraline, fenfluramine, or dexfenfluramine; appetite-suppressant agents acting through dopamine mechanisms, eg, apomorphine; appetite-suppressant agents acting through histaminergic mechanisms (eg, histamine mimetics, H3 receptor modulators); enhancers of energy expenditure

such as beta-3 adrenergic agonists and stimulators of uncoupling protein function; leptin and leptin mimetics; neuropeptide Y antagonists; melanocortin-1, 3 and 4 receptor modulators; cholecystokinin agonists; glucagon-like peptide-1 (GLP-1) mimetics and analogues (eg, Exendin); androgens (eg, dehydroepiandrosterone and derivatives such as etiocholandione),
5 testosterone, anabolic steroids (eg, oxandrolone), and steroidal hormones; galanin receptor antagonists; cytokine agents such as ciliary neurotrophic factor; amylase inhibitors; enterostatin agonists/mimetics; orexin/hypocretin antagonists; urocortin antagonists; bombesin agonists; modulators of protein
10 kinase A; corticotropin-releasing factor mimetics; cocaine- and amphetamine-regulated transcript mimetics; calcitonin-gene related peptide mimetics; and fatty acid synthase inhibitors.

There remains a need to provide an effective treatment for glucose related disorders such as elevated glucose levels, Type 2 diabetes mellitus,
15 Syndrome X, and the like. There also remains a need to provide an effective treatment for glucose related disorders which also slows or prevents the progression and / or development of Type 2 diabetes mellitus.

SUMMARY OF THE INVENTION

20 The present invention is directed to methods of co-therapy for the treatment and prevention of glucose-related disorders, said methods comprising administering to a subject in need thereof a therapeutically effective amount of co-therapy comprising (a) metformin or a pharmaceutically acceptable salt thereof and (b) a compound of formula (I)



25

wherein Ring A and Ring B are one of the followings:

(1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; or

5 (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, or an optionally substituted unsaturated fused heterobicyclic ring wherein Y is linked to the heterocyclic ring of the fused heterobicyclic ring; or

(3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, wherein the sugar moiety X-(sugar) and the moiety -Y-(Ring B) are both
10 on the same heterocyclic ring of the fused heterobicyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring;

15 X is a carbon atom or a nitrogen atom; and

Y is $-(CH_2)_n-$ (wherein n is 1 or 2);

or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

The present invention is further directed to methods of co-therapy for the treatment and prevention of glucose-related disorders, said methods
20 comprising administering to a subject in need thereof a therapeutically effective amount of co-therapy comprising (a) glyburide and (b) a compound of formula (I) or pharmaceutically acceptable salt thereof.

The present invention is further directed to (a) a compound of formula (I) or pharmaceutically acceptable salt thereof in combination with (b) metformin or
25 a pharmaceutically acceptable salt thereof for use in the treatment and prevention of glucose-related disorders

The present invention is further directed to (a) a compound of formula (I) or pharmaceutically acceptable salt thereof in combination with (b) metformin or a pharmaceutically acceptable salt thereof and (c) a sulfonylurea (preferably
30 glyburide) or pharmaceutically acceptable salt thereof for use in the treatment and prevention of glucose-related disorders.

The present invention is further directed to methods of co-therapy for the treatment and prevention of glucose-related disorders, said methods

comprising administering to a subject in need thereof a therapeutically effective amount of co-therapy comprising (a) metformin or a pharmaceutically acceptable salt thereof and (b) a compound of formula (I) or pharmaceutically acceptable salt thereof and (c) a sulfonylurea (preferably glyburide) or
5 pharmaceutically acceptable salt thereof.

The present invention is further directed to a pharmaceutical composition comprising (a) metformin or a pharmaceutically acceptable salt thereof, (b) a compound of formula (I) or pharmaceutically acceptable salt thereof and (c) a pharmaceutically acceptable excipient. An illustration of the
10 invention is a pharmaceutical composition made by mixing comprising (a) metformin or a pharmaceutically acceptable salt thereof, (b) a compound of formula (I) or pharmaceutically acceptable salt thereof and (c) a pharmaceutically acceptable excipient. Illustrating the invention is a process for making a pharmaceutical composition comprising mixing comprising (a)
15 metformin or a pharmaceutically acceptable salt thereof, (b) a compound of formula (I) or pharmaceutically acceptable salt thereof and (c) a pharmaceutically acceptable excipient.


The present invention is further directed to a pharmaceutical composition comprising (a) a sulfonylurea (preferably glyburide) or a
20 pharmaceutically acceptable salt thereof, (b) a compound of formula (I) or pharmaceutically acceptable salt thereof and (c) a pharmaceutically acceptable excipient. An illustration of the invention is a pharmaceutical composition made by mixing comprising (a) a sulfonylurea (preferably glyburide) or a pharmaceutically acceptable salt thereof, (b) a compound of formula (I) or
25 pharmaceutically acceptable salt thereof and (c) a pharmaceutically acceptable excipient. Illustrating the invention is a process for making a pharmaceutical composition comprising mixing comprising (a) a sulfonylurea (preferably glyburide) or a pharmaceutically acceptable salt thereof, (b) a compound of formula (I) or pharmaceutically acceptable salt thereof and (c) a
30 pharmaceutically acceptable excipient.

The present invention is further directed to a pharmaceutical composition comprising (a) metformin or a pharmaceutically acceptable salt thereof, (b) a compound of formula (I) or pharmaceutically acceptable salt thereof, (c) a

sulfonylurea or pharmaceutically acceptable salt thereof, and (d) a pharmaceutically acceptable excipient. An illustration of the invention is a pharmaceutical composition made by mixing comprising (a) metformin or a pharmaceutically acceptable salt thereof, (b) a compound of formula (I) or pharmaceutically acceptable salt thereof, (c) a sulfonylurea or pharmaceutically acceptable salt thereof, and (d) a pharmaceutically acceptable excipient. Illustrating the invention is a process for making a pharmaceutical composition comprising mixing comprising (a) metformin or a pharmaceutically acceptable salt thereof, (b) a compound of formula (I) or pharmaceutically acceptable salt thereof, (c) a sulfonylurea or pharmaceutically acceptable salt thereof, and (d) a pharmaceutically acceptable excipient.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to methods for the treatment and prevention of glucose related disorders comprising administering to a subject in need thereof a therapeutically effective amount of co-therapy comprising (a) metformin or a pharmaceutically acceptable salt thereof and (b) a compound of formula (I)




wherein Ring A, Ring B, X and Y are as herein defined; or pharmaceutically acceptable salt thereof.

The compounds of the formula (I) exhibit an inhibitory activity against sodium-dependent glucose transporter, such as for example SGLT2. The compounds of formula (I) exhibit an inhibitory activity against sodium-dependent glucose transporter, present in the intestine and the kidney of mammalian species, and further exhibit a blood glucose lowering effect. The compounds of formula (I) may be prepared according to the process as


disclosed in Nomura, S. et al., US Patent Publication, US 2005/0233988 A1, published October 20, 2005, which is incorporated by reference herein.

In an embodiment, the present invention is directed to methods for the treatment and prevention of glucose related disorders comprising administering to a subject in need thereof a therapeutically effective amount of co-therapy comprising (a) metformin or a pharmaceutically acceptable salt thereof and (b) a compound of formula (I-X)




or pharmaceutically acceptable salt thereof. In certain preferred embodiments, the compound of formula (I-X) is the crystalline form of the hemihydrate of the compound of Formula (I-X), as described in WO 2008/069327, the disclosure of which is hereby incorporated by reference in its entirety.

In another embodiment, the present invention is directed to methods for the treatment and prevention of glucose related disorders comprising administering to a subject in need thereof a therapeutically effective amount of co-therapy comprising (a) metformin or a pharmaceutically acceptable salt thereof and (b) a compound of formula (I-Y)



or pharmaceutically acceptable salt thereof.

The present invention is further directed to methods for the treatment
 5 and prevention of glucose related disorders comprising administering to a
 subject in need thereof a therapeutically effective amount of co-therapy
 comprising (a) a sulfonylurea (preferably glyburide) or a pharmaceutically
 acceptable salt thereof, and (b) a compound of formula (I)



10 wherein Ring A, Ring B, X and Y are as herein defined; or
 pharmaceutically acceptable salt thereof. In another embodiment, the present
 invention is directed to methods for the treatment and prevention of glucose
 related disorders comprising administering to a subject in need thereof a
 therapeutically effective amount of co-therapy comprising (a) a sulfonylurea
 15 (preferably glyburide) or a pharmaceutically acceptable salt thereof, and (b) a
 compound of formula (I-X) or pharmaceutically acceptable salt thereof. In
 another embodiment, the present invention is directed to methods for the
 treatment and prevention of glucose related disorders comprising administering
 to a subject in need thereof a therapeutically effective amount of co-therapy

comprising (a) a sulfonylurea (preferably glyburide) or a pharmaceutically acceptable salt thereof, and (b) a compound of formula (I-Y) or pharmaceutically acceptable salt thereof.

Metformin and more particularly metformin hydrochloride, (also known
5 by the trade names GLUCOPHAGE, RIOMET, FORTAMET, GLUMETZA, OBIMET, DIANBEN, DIABEX, DIAFORMIN, and others) is an oral anti-diabetic drug of the biguanide class. Metformin is a first-line therapy for Type 2 diabetes mellitus, particularly in overweight and obese people. The usual starting dose of metformin (for example, as metformin hydrochloride tablets) in
10 the United States and certain other countries is 500 mg twice a day or 850 mg once a day, given with meals. The daily dosage may be increases in increments of 500 mg weekly or 850 mg every 2 weeks, up to a total of 2000 mg per day, given in divided doses. Patients can also be titrated from 500 mg twice a day to 850 mg twice a day after 2 weeks. For those patients requiring
15 additional glycemic control, metformin may be given to a maximum daily dose of 2550 mg per day. Doses above 2000 mg may be better tolerated given three times a day with meals. Preferably, the metformin or pharmaceutically acceptable salt thereof is metformin hydrochloride.

Glyburide (also known as glibenclamide, and further known by the trade
20 names DIABETA, GLYNASE PRESTAB, MICRONASE and others) is an oral anti-diabetic of the sulfonylurea class. Glyburide is used for the treatment of Type II diabetes mellitus and works by inhibiting ATP-sensitive potassium channels in pancreatic beta cells. This inhibition causes cell membrane depolarization, which causes voltage-dependent calcium channels to open,
25 which in turn causes an increase in intracellular calcium in the beta cell, which stimulates insulin release. The starting dosage for glyburide is typically 2.5 mg to 5 mg (1.5 gm to 3 mg, if administered as micronized glyburide) taken daily with meals. As needed, glyburide dosages may be gradually increased (in steps of 2.5 mg or less per week) up to 20 mg daily (or up to 12 mg daily if
30 administered as micronized glyburide). Glyburide may also be administered in combination with metformin, and is available as in combination with metformin under the trade names GLUCOVANCE and GLIBOMET.

The present invention is further directed to methods for the treatment and prevention of glucose related disorders comprising administering to a subject in need thereof a therapeutically effective amount of co-therapy comprising (a) metformin or a pharmaceutically acceptable salt thereof and (b)
5 a compound of formula (I) or pharmaceutically acceptable salt thereof, and (c) a sulfonylurea or pharmaceutically acceptable salt thereof.

In an embodiment, the present invention is directed to methods for the treatment and prevention of glucose related disorders comprising administering to a subject in need thereof a therapeutically effective amount of co-therapy
10 comprising (a) metformin or a pharmaceutically acceptable salt thereof and (b) a compound of formula (I-X) or pharmaceutically acceptable salt thereof, and (c) a sulfonylurea or pharmaceutically acceptable salt thereof.

In another embodiment, the present invention is directed to methods for the treatment and prevention of glucose related disorders comprising
15 administering to a subject in need thereof a therapeutically effective amount of co-therapy comprising (a) metformin or a pharmaceutically acceptable salt thereof and (b) a compound of formula (I-Y) or pharmaceutically acceptable salt thereof, and (c) a sulfonylurea or pharmaceutically acceptable salt thereof.

The present invention is further directed to methods for the treatment
20 and prevention of glucose related disorders comprising administering to a subject in need thereof a therapeutically effective amount of co-therapy comprising (a) metformin or a pharmaceutically acceptable salt thereof and (b) a compound of formula (I) or pharmaceutically acceptable salt thereof, and (c) glyburide.

25 In another embodiment, the present invention is directed to methods for the treatment and prevention of glucose related disorders comprising administering to a subject in need thereof a therapeutically effective amount of co-therapy comprising (a) metformin or a pharmaceutically acceptable salt thereof and (b) a compound of formula (I-X) or pharmaceutically acceptable salt
30 thereof, and (c) glyburide.

In another embodiment, the present invention is directed to methods for the treatment and prevention of glucose related disorders comprising administering to a subject in need thereof a therapeutically effective amount of

co-therapy comprising (a) metformin or a pharmaceutically acceptable salt thereof and (b) a compound of formula (I-Y) or pharmaceutically acceptable salt thereof, and (c) glyburide.

Sulfonylureas are a class of pharmaceutical compounds which increase
5 insulin production by stimulating pancreatic beta cells, and therefore act as
insulin secretagogues. The primary mechanism of action of sulfonylureas is to
close ATP-sensitive potassium channels in the beta-cell plasma membrane,
initiating a chain of events that result in insulin release. Suitable examples of
sulfonylureas include, but are not limited to chlorpropamide, tolazamide,
10 tolbutamide, glyburide, glipizide, glimepiride, and like. One skilled in the art can
readily determine dosages and regimens for the administration of sulfonylureas,
for example by consulting the PDR (Physician's Desk Reference) and / or the
FDA required drug literature included with the pharmaceutical agent. For
example, a representative dosage for chlorpropamide (DIABINESE®) is 100-
15 250 mg QD; for tolazamide (TOLINASE®) is 250 mg QD or BID; for
tolbutamide (ORINASE®) is 1000 mg BID or TID; for glimepiride (AMARYL®)
is 2 mg QD; for glipizide (GLUCOTROL®) is 5-10 mg QD or BID; and for
glyburide (DIABETA®, MICRONASE®) is 2.5-5 mg QD or BID.

In an embodiment of the present invention, the sulfonylurea is selected
20 from the group consisting of chlorpropamide, tolazamide and tolbutamide;
wherein the sulfonylurea is present in (administered in) an amount in the range
of from about 100 mg to about 3000 mg, or any amount or range therein,
preferably in an amount in the range of from about 100 mg to about 1000 mg,
or any amount or range therein. In another embodiment of the present
25 invention, the sulfonylurea is selected from the group consisting of glyburide,
glipizide and glimepiride; and is present in an amount in the range of from
about 0.1 mg to about 50 mg, or any amount or range therein, preferably in an
amount in the range of from about 1.0 mg to about 50 mg, more preferably in
an amount in the range of from about 2.0 mg to about 25 mg, or any amount or
30 range therein.

In another embodiment of the present invention, the sulfonylurea is
glyburide; wherein the glyburide is present in (administered in) an amount in the
range of from about 1.0 mg to about 20 mg daily, or any amount or range

therein; preferably in an amount in the range of from about 2.5 mg to about 20 mg, daily, or any amount or range therein, more preferably in an amount in the range of from about 2.5 mg to about 10 mg daily, or any amount or range therein, more preferably in an amount in the range of from about 2.5 mg to
5 about 5 mg daily, or any amount or range therein.

The present invention is further directed to a pharmaceutical composition comprising a therapeutically effective amount of co-therapy comprising (a) metformin or a pharmaceutically acceptable salt thereof; and (b) a compound of formula (I) or pharmaceutically acceptable salt thereof. The present invention
10 is further directed to a pharmaceutical composition comprising a therapeutically effective amount of co-therapy comprising (a) glyburide; and (b) a compound of formula (I) or pharmaceutically acceptable salt thereof.

The present invention is further directed to a pharmaceutical composition comprising a therapeutically effective amount of co-therapy comprising (a)
15 metformin or a pharmaceutically acceptable salt thereof; (b) a compound of formula (I) or pharmaceutically acceptable salt thereof, and (c) a sulfonylurea or pharmaceutically acceptable salt thereof.

In an embodiment, the present invention is directed to a pharmaceutical composition comprising (a) metformin or a pharmaceutically acceptable salt thereof and (b) a compound of formula (I-X) or pharmaceutically acceptable salt thereof. In another embodiment, the present invention is directed to a pharmaceutical composition comprising (a) metformin or a pharmaceutically acceptable salt thereof and (b) a compound of formula (I-Y) or pharmaceutically acceptable salt thereof. In another embodiment of the present invention, the
20 pharmaceutical composition is an immediate release dosage form. In another embodiment of the present invention, the pharmaceutical composition is an extended release dosage form, wherein the dosage form releases the one or more of the active ingredients over a period of time in the range of from about 8 to about 24 hours, or any amount or range therein.

30 In an embodiment, the present invention is directed to a pharmaceutical composition comprising (a) glyburide and (b) a compound of formula (I-X) or pharmaceutically acceptable salt thereof. In another embodiment, the present invention is directed to a pharmaceutical composition comprising (a) glyburide

and (b) a compound of formula (I-Y) or pharmaceutically acceptable salt thereof. In another embodiment of the present invention, said pharmaceutical composition is an immediate release dosage form. In another embodiment of the present invention, the pharmaceutical composition is an extended release dosage form, wherein the dosage form releases the one or more of the active ingredients over a period of time in the range of from about 8 to about 24 hours, or any amount or range therein.

In an embodiment, the present invention is directed to a pharmaceutical composition comprising (a) metformin or a pharmaceutically acceptable salt thereof, (b) a compound of formula (I-X) or pharmaceutically acceptable salt thereof, and (c) a sulfonylurea or pharmaceutically acceptable salt thereof. In another embodiment, the present invention is directed to a pharmaceutical composition comprising (a) metformin or a pharmaceutically acceptable salt thereof, (b) a compound of formula (I-Y) or pharmaceutically acceptable salt thereof, and (c) a sulfonylurea or pharmaceutically acceptable salt thereof. In another embodiment of the present invention, the pharmaceutical composition is an immediate release dosage form. In another embodiment of the present invention, the pharmaceutical composition is an extended release dosage form, wherein the dosage form releases one or more of the active ingredients over a period of time in the range of from about 8 to about 24 hours, or any amount or range therein, preferably over a time in the range of from about 8 hours to about 12 hours, or any amount or range therein.

In an embodiment, the present invention is directed to a pharmaceutical composition wherein the metformin or pharmaceutically acceptable salt thereof is metformin hydrochloride. In another embodiment, the present invention is directed to a pharmaceutical composition wherein the metformin hydrochloride is present at a dosage amount in the range of from about 100 mg to about 2000 mg, preferably from about 250 mg to about 2000 mg, preferably from about 250 mg to about 1000 mg, or any amount or range therein. In another embodiment, the present invention is directed to a pharmaceutical composition wherein the metformin hydrochloride is present at a dosage amount selected from the group consisting of 250 mg, 500 mg, 750 mg, 850 mg, 1000 mg, 1700 mg and 2000 mg.

In an embodiment, the present invention is directed to a pharmaceutical composition wherein the glyburide is present at a dosage amount in the range of from about 1.0 mg to about 20.0 mg, preferably from about 2.5 mg to about 20.0 mg, more preferably from about 2.5 mg to about 10.0 mg, or any amount
5 or range therein. In another embodiment, the present invention is directed to a pharmaceutical composition wherein the glyburide is present at a dosage amount selected from the group consisting of 1.0, 1.5, 2.5, 5.0, 7.5, 10, 12.5, 15 and 20 mg.

In an embodiment, the present invention is directed to a pharmaceutical
10 composition wherein the compound of formula (I) or pharmaceutically acceptable salt thereof is selected from the group consisting of a compound of formula (I-X) or pharmaceutically acceptable salt thereof; and a compound of formula (I-Y) or pharmaceutically acceptable salt thereof. In another embodiment, the present invention is directed to a pharmaceutical composition
15 wherein the compound of formula (I) or pharmaceutically acceptable salt thereof is the compound of formula (I-X) or pharmaceutically acceptable salt thereof.

In another embodiment, the present invention is directed to a pharmaceutical composition wherein the compound of formula (I-X) or
20 pharmaceutically acceptable salt thereof is present at a dosage amount in the range of from about 1 mg to about 500 mg, preferably from about 1 mg to about 300 mg, preferably from about 25 mg to about 300 mg, or any amount or range therein. In another embodiment, the present invention is directed to a pharmaceutical composition wherein the compound of formula (I-X) or
25 pharmaceutically acceptable salt thereof is present at a dosage amount in the range of from about 25 mg to about 300 mg, preferably selected from the group consisting of 50 mg, 100 mg, 150 mg, 200 mg and 300 mg.

In another embodiment, the present invention is directed to a pharmaceutical composition wherein the compound of formula (I-Y) or
30 pharmaceutically acceptable salt thereof is present at a dosage amount in the range of from 1 mg to about 500 mg, preferably from about 1 mg to about 100 mg, or from about 1 mg to about 50 mg, or any amount or range therein. In another embodiment, the present invention is directed to a pharmaceutical

composition wherein the compound of formula (I-Y) or pharmaceutically acceptable salt thereof is present at a dosage amount selected from the group consisting of 1 mg, 5 mg, 10 mg, 25 mg, 50 mg and 100 mg.

5 In yet another embodiment, the present invention is directed to a pharmaceutical composition comprising:

(a) metformin or a pharmaceutically acceptable salt thereof;

(b) a compound of formula (I) or pharmaceutically acceptable salt thereof selected from the group consisting of a compound of formula (I-X) or pharmaceutically acceptable salt thereof; and a compound of formula (I-Y) or
10 pharmaceutically acceptable salt thereof;

wherein the metformin or pharmaceutically acceptable salt thereof is present in an amount in the range of from about 100 mg to about 2000 mg, preferably from about 500 mg to about 1000 mg, or any amount or range therein; and

15 wherein the compound of formula (I) or pharmaceutically acceptable salt thereof is present in an amount in the range of from about 1 mg to about 1000 mg, or any amount or range therein (preferably in an amount in the range of from about 1 mg to about 500 mg, or any amount or range therein, more preferably in an amount in the range of from about 10 mg to about 300 mg, or
20 any amount or range therein).

In yet another embodiment, the present invention is directed to a pharmaceutical composition comprising:

(a) glyburide; wherein the glyburide is present in an amount in the range of from about 1.0 mg to about 20 mg, preferably from about 2.5 mg to about 20
25 mg, or any amount or range therein; and

(b) a compound of formula (I) or pharmaceutically acceptable salt thereof (wherein the compound of formula (I) or pharmaceutically acceptable salt thereof is preferably selected from the group consisting of a compound of formula (I-X) or pharmaceutically acceptable salt thereof; and a compound of
30 formula (I-Y) or pharmaceutically acceptable salt thereof); wherein the compound of formula (I) or pharmaceutically acceptable salt thereof is present in an amount in the range of from about 1 mg to about 1000 mg, or any amount or range therein (preferably in an amount in the range of from about 1 mg to

about 500 mg, or any amount or range therein, more preferably in an amount in the range of from about 10 mg to about 300 mg, or any amount or range therein).

In an embodiment of the present invention, the compound of formula (I)
5 is a compound of formula (I-X) and is present in the pharmaceutical composition in an amount in the range of from about 1 mg to about 1000 mg, or any amount or range therein, preferably in an amount in the range of from about 50 mg to about 300 mg, or any amount or range therein. In another embodiment of the present invention, the compound of formula (I) is a
10 compound of formula (I-Y) and is present in the pharmaceutical composition in an amount in the range of from about 1 mg to about 1000 mg, or any amount or range therein, preferably in an amount in the range of from about 1 mg to about 100 mg, or any amount or range therein, more preferably in an amount in the range of from about 10 mg to about 50 mg, or any range thereof.

15

In yet another embodiment, the present invention is directed to a pharmaceutical composition comprising:

(a) metformin or a pharmaceutically acceptable salt thereof; wherein the metformin or pharmaceutically acceptable salt thereof is present in an amount
20 in the range of from about 100 mg to about 2000 mg, preferably from about 500 mg or about 1000 mg, or any amount or range therein;

(b) a compound of formula (I) or pharmaceutically acceptable salt thereof (wherein the compound of formula (I) is preferably selected from the group consisting of a compound of formula (I-X) or pharmaceutically acceptable salt thereof; and a compound of formula (I-Y) or pharmaceutically acceptable salt thereof); wherein the compound of formula (I) or pharmaceutically acceptable salt thereof is present in an amount in the range of from about 1 mg to about 1000 mg, or any amount or range therein (preferably in an amount in the range of from about 1 mg to about 500 mg, or any amount or range therein, more
25 preferably in an amount in the range of from about 10 mg to about 300 mg, or any amount or range therein); and
30

and (c) glyburide; wherein the glyburide is present in an amount in the range of from about 1.0 mg to about 20 mg, preferably from about 2.5 mg to about 20 mg, or any amount or range therein.

In an embodiment, the present invention is directed to a pharmaceutical composition comprising (a) metformin hydrochloride; (b) a compound of formula (I) or pharmaceutically acceptable salt thereof selected from the group consisting of a compound of formula (I-X) or pharmaceutically acceptable salt thereof; and a compound of formula (I-Y) or pharmaceutically acceptable salt thereof; and one or more pharmaceutically acceptable excipients. The pharmaceutically acceptable excipients, include but are not limited to, disintegrants, binders, diluents, lubricants, stabilizers, antioxidants, surfactants, colorants, plasticizers, coatings and the like. More particularly, suitable pharmaceutical excipients comprise one or more of the following: (i) diluents such as lactose, microcrystalline cellulose, dicalcium phosphate, starch and the like; (ii) binders such as polyvinylpyrrolidone (such as POVIDONE), methylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose (such as METHOCELTM E-5), and the like; (iii) disintegrants such as sodium starch glycolate, croscarmellose sodium, crospovidone and the like; (iv) wetting agents such as surfactants, such as sodium lauryl stearate, polysorbate 20, and the like; (v) lubricants such as magnesium stearate, sodium stearyl fumarate, talc, and the like; (vi) flow promoters or glidants such as colloidal silicon dioxide, talc and the like; and other excipients known to be useful in the preparation of pharmaceutical compositions. Additional suitable pharmaceutical excipients and their properties may be found in texts such as Handbook of Pharmaceutical
Excipients, Edited by R.C. Rowe, P.J. Sheskey & P.J. Weller, Fourth Edition (Published by Pharmaceutical Press, a Division of Royal Pharmaceutical Society of Great Britain). In another embodiment, the present invention is directed to a pharmaceutical composition as described above, further comprising a sulfonylurea or pharmaceutically acceptable salt thereof.

Fillers or diluents for use in the pharmaceutical compositions of the present invention include fillers or diluents typically used in the formulation of pharmaceuticals. Examples of fillers or diluents for use in accordance with the present invention include but are not limited to sugars such as lactose,

dextrose, glucose, sucrose, cellulose, starches and carbohydrate derivatives, polysaccharides (including dextrates and maltodextrin), polyols (including mannitol, xylitol, and sorbitol), cyclodextrins, calcium carbonates, magnesium carbonates, microcrystalline cellulose, combinations thereof, and the like.

5 Binders for use in the pharmaceutical compositions of the present invention include binders commonly used in the formulation of pharmaceuticals. Examples of binders for use in accordance with the present invention include but are not limited to cellulose derivatives (including hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose, and sodium carboxymethyl
10 cellulose), glycol, sucrose, dextrose, corn syrup, polysaccharides (including acacia, targaranth, guar, alginates and starch), corn starch, pregelatinized starch, modified corn starch, gelatin, polyvinylpyrrolidone, polyethylene, polyethylene glycol, combinations thereof and the like.

Disintegrants for use in the pharmaceutical compositions of the present
15 invention include disintegrants commonly used in the formulation of pharmaceuticals. Examples of disintegrants for use in accordance with the present invention include but are not limited to starches, and crosslinked starches, celluloses and polymers, combinations thereof and the like. Representative disintegrants include microcrystalline cellulose, croscarmellose
20 sodium, alginic acid, sodium alginate, crospovidone, cellulose, agar and related gums, sodium starch glycolate, corn starch, potato starch, sodium starch glycolate, Veegum HV, methylcellulose, agar, bentonite, sodium carboxymethylcellulose, calcium carboxymethylcellulose, carboxymethylcellulose, alginic acid, guar gum combinations thereof, and the
25 like.

Lubricants, glidants or anti-tacking agents for use in the pharmaceutical compositions of the present invention include lubricants, glidants and anti-tacking agents commonly used in the formulation of pharmaceuticals. Examples for use in accordance with the present invention include but are not
30 limited to magnesium carbonate, magnesium laurylsulphate, calcium silicate, talc, fumed silicon dioxide, combinations thereof, and the like. Other useful lubricants include but are not limited to magnesium stearate, calcium stearate, stearic acid, sodium stearyl fumarate, polyethylene glycol, sodium lauryl

sulphate, magnesium lauryl sulphate, sodium benzoate, colloidal silicon dioxide, magnesium oxide, magnesium silicate, mineral oil, hydrogenated vegetable oils, waxes, glyceryl behenate, polyethylene glycol, and combinations thereof, and the like.

5 Surfactants for use in the pharmaceutical compositions of the present invention include surfactants commonly used in the formulation of pharmaceuticals. Examples of surfactants for use in accordance with the present invention include but are not limited to ionic and nonionic surfactants or wetting agents commonly used in the formulation of pharmaceuticals, such as
10 ethoxylated castor oil, polyglycolized glycerides, acetylated monoglycerides, sorbitan fatty acid esters, poloxamers, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene derivatives, monoglycerides or ethoxylated derivatives thereof, diglycerides or polyoxyethylene derivatives thereof, sodium docusate, sodium laurylsulfate, cholic acid or derivatives thereof, lecithins, phospholipids,
15 combinations thereof, and the like.

Other polymers commonly used as excipients in pharmaceutical compositions include, but are not limited to, methylcellulose (MC), ethylcellulose (EC), hydroxyethylcellulose (HEC), methyl hydroxyethylcellulose (MHEC), hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose
20 (HPMC), sodium carboxymethylcellulose (NaCMC), and the like.

The pharmaceutical compositions can further comprise antioxidants and chelating agents. For example, the pharmaceutical formulations can comprise butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), propyl gallate (PG), sodium metabisulfite, ascorbyl palmitate, potassium metabisulfite,
25 disodium EDTA (ethylenediamine tetraacetic acid; also known as disodium edentate), EDTA, tartaric acid, citric acid, citric acid monohydrate, and sodium sulfite.

The pharmaceutical compositions may further optionally comprise one or more flow regulators (or glidants). Flow regulators may be present in powders
30 or granules and are admixed in order to increase their flowability of the composition during manufacture, particularly in the preparation of tablets produced by pressing powders or granules. Flow regulators which can be

employed include, but are not limited to, highly disperse silicon dioxide (Aerosil) or dried starch.

One skilled in the art will readily recognize that the appropriate pharmaceutically acceptable excipients are selected such that they are
5 compatible with other excipients and do not bind with the drug compound(s) (active ingredient(s)) or cause drug degradation.

Tablet compositions may further optionally comprise a coating. Suitable coatings include, but are not limited to, film-forming polymers, such as, for example, those from the group of the cellulose derivatives, dextrans, starches,
10 natural gums, such as, for example, gum arabic, xanthans, alginates, polyvinyl alcohol, polymethacrylates and derivatives thereof, such as, for example, Eudragit®; which may be applied to the tablet as solutions or suspensions by means of the various pharmaceutical conventional methods, such as, for example, film coating. The coating is typically applied as a
15 solutions/suspensions which, in addition to any film-forming polymer present, may further comprise one or more adjuvants, such as hydrophilisers, plasticisers, surfactants, dyes and white pigments, such as, for example, titanium dioxide.

In certain embodiments of the present invention, the pharmaceutical
20 composition preferably comprising between about 5% and about 50% by weight of diluents (relative to the total weight of the composition or composition layer), more preferably between about 5% and about 25% by weight diluent, more preferably still about 7% diluent.

In additional embodiments of the present invention, the pharmaceutical
25 composition preferably comprising between about 1% and about 10% by weight of binder (relative to the total weight of the composition or composition layer), more preferably between about 3% and about 5% by weight binder, more preferably still about 4% binder.

In additional embodiments of the present invention, the pharmaceutical
30 composition preferably comprising between about 1% and about 10% by weight of disintegrant (relative to the total weight of the composition or composition layer), more preferably between about 2% and about 5% by weight disintegrant, more preferably still about 3% disintegrant.

In additional embodiments of the present invention, the pharmaceutical composition preferably comprising between about 0% and about 5% by weight of wetting agent (relative to the total weight of the composition or composition layer), more preferably between about 0.1% and about 2% by weight wetting agent, more preferably still about 0.3% wetting agent.

In additional embodiments of the present invention, the pharmaceutical composition preferably comprising between about 0% and about 3% by weight of lubricant (relative to the total weight of the composition or composition layer), more preferably between about 0.1% and about 2% by weight lubricant, more preferably still about 0.5% lubricant.

Definitions

The term “**halogen atom**” or “**halo**” means chlorine, bromine, fluorine and iodine, and chlorine and fluorine are preferable.

The term “**alkyl group**” means a straight or branched saturated monovalent hydrocarbon chain having 1 to 12 carbon atoms. The straight chain or branched chain alkyl group having 1 to 6 carbon atoms is preferable, and the straight chain or branched chain alkyl group having 1 to 4 carbon atoms is more preferable. Examples thereof are methyl group, ethyl group, propyl group, isopropyl group, butyl group, t-butyl group, isobutyl group, pentyl group, hexyl group, isohexyl group, heptyl group, 4,4-dimethylpentyl group, octyl group, 2,2,4-trimethylpentyl group, nonyl group, decyl group, and various branched chain isomers thereof. Further, the alkyl group may optionally and independently be substituted by 1 to 4 substituents as listed below, if necessary.

The term “**alkylene group**” or “**alkylene**” means a straight or branched divalent saturated hydrocarbon chain having 1 to 12 carbon atoms. The straight chain or branched chain alkylene group having 1 to 6 carbon atoms is preferable, and the straight chain or branched chain alkylene group having 1 to 4 carbon atoms is more preferable. Examples thereof are methylene group, ethylene group, propylene group, trimethylene group, etc. If necessary, the alkylene group may optionally be substituted in the same manner as the above-mentioned “alkyl group”. Where alkylene groups as defined above attach at

two different carbon atoms of the benzene ring, they form an annelated five, six or seven membered carbocycle together with the carbon atoms to which they are attached, and may optionally be substituted by one or more substituents defined below.

5 The term “**alkenyl group**” means a straight or branched monovalent hydrocarbon chain having 2 to 12 carbon atoms and having at least one double bond. Preferable alkenyl group is a straight chain or branched chain alkenyl group having 2 to 6 carbon atoms, and the straight chain or branched chain alkenyl group having 2 to 4 carbon atoms is more preferable. Examples
10 thereof are vinyl group, 2-propenyl group, 3-butenyl group, 2-butenyl group, 4-pentenyl group, 3-pentenyl group, 2-hexenyl group, 3-hexenyl group, 2-heptenyl group, 3-heptenyl group, 4-heptenyl group, 3-octenyl group, 3-nonenyl group, 4-decenyl group, 3-undecenyl group, 4-dodecenyl group, 4,8,12-tetradecatrienyl group, etc. The alkenyl group may optionally and
15 independently be substituted by 1 to 4 substituents as mentioned below, if necessary.

 The term “**alkenylene group**” means a straight or branched divalent hydrocarbon chain having 2 to 12 carbon atoms and having at least one double bond. The straight chain or branched chain alkenylene group having 2 to 6
20 carbon atoms is preferable, and the straight chain or branched chain alkenylene group having 2 to 4 carbon atoms is more preferable. Examples thereof are vinylene group, propenylene group, butadienylene group, etc. If necessary, the alkylene group may optionally be substituted by 1 to 4 substituents as mentioned below, if necessary. Where alkenylene groups as
25 defined above attach at two different carbon atoms of the benzene ring, they form an annelated five, six or seven membered carbocycle (e.g., a fused benzene ring) together with the carbon atoms to which they are attached, and may optionally be substituted by one or more substituents defined below.

 The term “**alkynyl group**” means a straight or branched monovalent
30 hydrocarbon chain having at least one triple bond. The preferable alkynyl group is a straight chain or branched chain alkynyl group having 2 to 6 carbon atoms, and the straight chain or branched chain alkynyl group having 2 to 4 carbon atoms is more preferable. Examples thereof are 2-propynyl group, 3-

butynyl group, 2-butynyl group, 4-pentynyl group, 3-pentynyl group, 2-hexynyl group, 3-hexynyl group, 2-heptynyl group, 3-heptynyl group, 4-heptynyl group, 3-octynyl group, 3-nonynyl group, 4-decynyl group, 3-undecynyl group, 4-dodecynyl group, etc. The alkynyl group may optionally and independently be substituted by 1 to 4 substituents as mentioned below, if necessary.

The term “**cycloalkyl group**” means a monocyclic or bicyclic monovalent saturated hydrocarbon ring having 3 to 12 carbon atoms, and the monocyclic saturated hydrocarbon group having 3 to 7 carbon atoms is more preferable. Examples thereof are a monocyclic alkyl group and a bicyclic alkyl group such as cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, cycloheptyl group, cyclooctyl group, cyclodecyl group, etc. These groups may optionally and independently be substituted by 1 to 4 substituents as mentioned below, if necessary. The cycloalkyl group may optionally be condensed with a saturated hydrocarbon ring or an unsaturated hydrocarbon ring (said saturated hydrocarbon ring and unsaturated hydrocarbon ring may optionally contain an oxygen atom, a nitrogen atom, a sulfur atom, SO or SO₂ within the ring, if necessary), and the condensed saturated hydrocarbon ring and the condensed unsaturated hydrocarbon ring may be optionally and independently be substituted by 1 to 4 substituents as mentioned below.

The term “**cycloalkylidene group**” means a monocyclic or bicyclic divalent saturated hydrocarbon ring having 3 to 12 carbon atoms, and the monocyclic saturated hydrocarbon group having 3 to 6 carbon atoms is preferable. Examples thereof are a monocyclic alkylidene group and a bicyclic alkylidene group such as cyclopropylidene group, cyclobutylidene group, cyclopentylidene group, cyclohexylidene group, etc. These groups may optionally and independently be substituted by 1 to 4 substituents as mentioned below, if necessary. Besides, the cycloalkylidene group may optionally be condensed with a saturated hydrocarbon ring or an unsaturated hydrocarbon ring (said saturated hydrocarbon ring and unsaturated hydrocarbon ring may optionally contain an oxygen atom, a nitrogen atom, a sulfur atom, SO or SO₂ within the ring, if necessary), and the condensed saturated hydrocarbon ring

and the unsaturated hydrocarbon ring may be optionally and independently be substituted by 1 to 4 substituents as mentioned below.

The term “**cycloalkenyl group**” means a monocyclic or bicyclic monovalent unsaturated hydrocarbon ring having 4 to 12 carbon atoms and having at least one double bond. The preferable cycloalkenyl group is a monocyclic unsaturated hydrocarbon group having 4 to 7 carbon atoms. Examples thereof are monocyclic alkenyl groups such as cyclopentenyl group, cyclopentadienyl group, cyclohexenyl group, etc. These groups may optionally and independently be substituted by 1 to 4 substituents as mentioned below, if necessary. Besides, the cycloalkenyl group may optionally be condensed with a saturated hydrocarbon ring or an unsaturated hydrocarbon ring (said saturated hydrocarbon ring and unsaturated hydrocarbon ring may optionally contain an oxygen atom, a nitrogen atom, a sulfur atom, SO or SO₂ within the ring, if necessary), and the condensed saturated hydrocarbon ring and the unsaturated hydrocarbon ring may be optionally and independently be substituted by 1 to 4 substituents as mentioned below.

The term “**cycloalkynyl group**” means a monocyclic or bicyclic unsaturated hydrocarbon ring having 6 to 12 carbon atoms, and having at least one triple bond. The preferable cycloalkynyl group is a monocyclic unsaturated hydrocarbon group having 6 to 8 carbon atoms. Examples thereof are monocyclic alkynyl groups such as cyclooctynyl group, cyclodecynyl group. These groups may optionally be substituted by 1 to 4 substituents as mentioned below, if necessary. Besides, the cycloalkynyl group may optionally and independently be condensed with a saturated hydrocarbon ring or an unsaturated hydrocarbon ring (said saturated hydrocarbon ring and unsaturated hydrocarbon ring may optionally contain an oxygen atom, a nitrogen atom, a sulfur atom, SO or SO₂ within the ring, if necessary), and the condensed saturated hydrocarbon ring or the unsaturated hydrocarbon ring may be optionally and independently be substituted by 1 to 4 substituents as mentioned below.

The term “**aryl group**” means a monocyclic or bicyclic monovalent aromatic hydrocarbon group having 6 to 10 carbon atoms. Examples thereof are phenyl group, naphthyl group (including 1-naphthyl group and 2-naphthyl

group). These groups may optionally and independently be substituted by 1 to 4 substituents as mentioned below, if necessary. Besides, the aryl group may optionally be condensed with a saturated hydrocarbon ring or an unsaturated hydrocarbon ring (said saturated hydrocarbon ring and unsaturated hydrocarbon ring may optionally contain an oxygen atom, a nitrogen atom, a sulfur atom, SO or SO₂ within the ring, if necessary), and the condensed saturated hydrocarbon ring or the unsaturated hydrocarbon ring may be optionally and independently be substituted by 1 to 4 substituents as mentioned below.

10 The term “**unsaturated monocyclic heterocyclic ring**” means an unsaturated hydrocarbon ring containing 1-4 heteroatoms independently selected from a nitrogen atom, an oxygen atom and a sulfur atom, and the preferable one is a 4- to 7-membered saturated or unsaturated hydrocarbon ring containing 1-4 heteroatoms independently selected from a nitrogen atom, an oxygen atom and a sulfur atom. Examples thereof are pyridine, pyrimidine, 15 pyrazine, furan, thiophene, pyrrole, imidazole, pyrazole, oxazole, isoxazole, 4,5-dihydrooxazole, thiazole, isothiazole, thiadiazole, triazole, tetrazole, etc. Among them, pyridine, pyrimidine, pyrazine, furan, thiophene, pyrrole, imidazole, oxazole, and thiazole can be preferably used. The “unsaturated 20 monocyclic heterocyclic ring” may optionally and independently be substituted by 1-4 substituents as mentioned below, if necessary.

 The term “**unsaturated fused heterobicyclic ring**” means hydrocarbon ring comprised of a saturated or a unsaturated hydrocarbon ring condensed with the above mentioned unsaturated monocyclic heterocyclic ring where said 25 saturated hydrocarbon ring and said unsaturated hydrocarbon ring may optionally contain an oxygen atom, a nitrogen atom, a sulfur atom, SO, or SO₂ within the ring, if necessary. The “unsaturated fused heterobicyclic ring” includes, for example, benzothiophene, indole, tetrahydrobenzothiophene, benzofuran, isoquinoline, thienothiophene, thienopyridine, quinoline, indoline, 30 isoindoline, benzothiazole, benzoxazole, indazole, dihydroisoquinoline, etc. Further, the “heterocyclic ring” also includes possible N- or S-oxides thereof.

 The term “**heterocyclyl**” means a monovalent group of the above-mentioned unsaturated monocyclic heterocyclic ring or unsaturated fused

heterobicyclic ring and a monovalent group of the saturated version of the above-mentioned unsaturated monocyclic heterocyclic or unsaturated fused heterobicyclic ring. If necessary, the heterocyclyl may optionally and independently be substituted by 1 to 4 substituents as mentioned below.

- 5 The term “**alkanoyl group**” means a formyl group and ones formed by binding an “alkyl group” to a carbonyl group.

 The term “**alkoxy group**” means ones formed by binding an “alkyl group” to an oxygen atom.

- The substituent for the above each group includes, for example, a
10 halogen atom (e.g., fluorine, chlorine, bromine, iodine), a nitro group, a cyano group, an oxo group, a hydroxy group, a mercapto group, a carboxyl group, a sulfo group, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkylidenemethyl group, a cycloalkenyl group, a cycloalkynyl group, an aryl group, a heterocyclyl group, an alkoxy group, an alkenyloxy group,
15 group, an alkynyloxy group, a cycloalkyloxy group, a cycloalkenyloxy group, a cycloalkynyloxy group, an aryloxy group, a heterocyclyloxy group, an alkanoyl group, an alkenylcarbonyl group, an alkynylcarbonyl group, a cycloalkylcarbonyl group, a cycloalkenylcarbonyl group, a cycloalkynylcarbonyl group, an arylcarbonyl group, a heterocyclylcarbonyl group, an alkoxycarbonyl group, an alkenyloxycarbonyl group, an alkynyloxycarbonyl group, a cycloalkyloxycarbonyl group, a cycloalkenyloxycarbonyl group, a cycloalkynyl-
20 oxycarbonyl group, an aryloxycarbonyl group, a heterocyclyloxycarbonyl group, an alkanoyloxy group, an alkenylcarbonyloxy group, an alkynylcarbonyloxy group, a cycloalkylcarbonyloxy group, a cycloalkenylcarbonyloxy group, a cycloalkynylcarbonyloxy group, an arylcarbonyloxy group, a hetero-
25 cyclylcarbonyloxy group, an alkylthio group, an alkenylthio group, an alkynylthio group, a cycloalkylthio group, a cycloalkenylthio group, a cycloalkynylthio group, an arylthio group, a heterocyclylthio group, an amino group, a mono- or di-alkylamino group, a mono- or di-alkanoylamino group, a mono- or di-alkoxy-
30 carbonylamino group, a mono- or di-arylcarbonylamino group, an alkylsulfinylamino group, an alkylsulfonylamino group, an arylsulfinylamino group, an arylsulfonylamino group, a carbamoyl group, a mono- or di-alkyl-carbamoyl group, a mono- or di-arylcarbamoyl group, an alkylsulfinyl group, an

alkenylsulfinyl group, an alkynylsulfinyl group, a cycloalkylsulfinyl group, a cycloalkenylsulfinyl group, a cycloalkynylsulfinyl group, an arylsulfinyl group, a heterocyclylsulfinyl group, an alkylsulfonyl group, an alkenylsulfonyl group, an alkynylsulfonyl group, a cycloalkylsulfonyl group, a cycloalkenylsulfonyl group, a cycloalkynylsulfonyl group, an arylsulfonyl group, and a heterocyclylsulfonyl group. Each group as mentioned above may optionally be substituted by these substituents.

Further, the terms such as a haloalkyl group, a halo-lower alkyl group, a haloalkoxy group, a halo-lower alkoxy group, a halophenyl group, or a haloheterocyclyl group mean an alkyl group, a lower alkyl group, an alkoxy group, a lower alkoxy group, a phenyl group or a heterocyclyl group (hereinafter, referred to as an alkyl group, etc.) being substituted by one or more halogen atoms, respectively. Preferable ones are an alkyl group, etc. being substituted by 1 to 7 halogen atoms, and more preferable ones are an alkyl group, etc. being substituted by 1 to 5 halogen atoms. Similarly, the terms such as a hydroxyalkyl group, a hydroxy-lower alkyl group, a hydroxyalkoxy group, a hydroxy-lower alkoxy group and a hydroxyphenyl group mean an alkyl group, etc., being substituted by one or more hydroxy groups. Preferable ones are an alkyl group, etc., being substituted by 1 to 4 hydroxy groups, and more preferable ones are an alkyl group, etc., being substituted by 1 to 2 hydroxy groups. Further, the terms such as an alkoxyalkyl group, a lower alkoxyalkyl group, an alkoxy-lower alkyl group, a lower alkoxy-lower alkyl group, an alkoxyalkoxy group, a lower alkoxyalkoxy group, an alkoxy-lower alkoxy group, a lower alkoxy-lower alkoxy group, an alkoxyphenyl group, and a lower alkoxyphenyl group means an alkyl group, etc., being substituted by one or more alkoxy groups. Preferable ones are an alkyl group, etc., being substituted by 1 to 4 alkoxy groups, and more preferable ones are an alkyl group, etc., being substituted by 1 to 2 alkoxy groups.

The terms "**arylalkyl**" and "**arylalkoxy**" as used alone or as part of another group refer to alkyl and alkoxy groups as described above having an aryl substituent.

The term "**lower**" used in the definitions for the formulae in the present specification means a straight or branched carbon chain having 1 to 6 carbon

atoms, unless defined otherwise. More preferably, it means a straight or branched carbon chain having 1 to 4 carbon atoms.

Examples of the optionally substituted unsaturated monocyclic heterocyclic ring of the present invention include an unsaturated monocyclic heterocyclic ring which may optionally be substituted by 1-5 substituents selected from the group consisting of a halogen atom, a nitro group, a cyano group, an oxo group, a hydroxyl group, a mercapto group, a carboxyl group, a sulfo group, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkylidenemethyl group, a cycloalkenyl group, a cycloalkynyl group, an aryl group, a heterocyclyl group, an alkoxy group, an alkenyloxy group, an alkynyloxy group, a cycloalkyloxy group, a cycloalkenyloxy group, a cycloalkynyloxy group, an aryloxy group, a heterocyclyloxy group, an alkanoyl group, an alkenylcarbonyl group, an alkynylcarbonyl group, a cycloalkylcarbonyl group, a cycloalkenylcarbonyl group, a cycloalkynylcarbonyl group, an arylcarbonyl group, a heterocyclylcarbonyl group, an alkoxycarbonyl group, an alkenyloxycarbonyl group, an alkynyloxycarbonyl group, a cycloalkyloxycarbonyl group, a cycloalkenyloxycarbonyl group, a cycloalkynyloxycarbonyl group, an aryloxycarbonyl group, a heterocyclyloxycarbonyl group, an alkanoyloxy group, an alkenylcarbonyloxy group, an alkynylcarbonyloxy group, a cycloalkylcarbonyloxy group, a cycloalkenylcarbonyloxy group, a cycloalkynylcarbonyloxy group, an arylcarbonyloxy group, a heterocyclylcarbonyloxy group, an alkylthio group, an alkenylthio group, an alkynylthio group, a cycloalkylthio group, a cycloalkenylthio group, a cycloalkynylthio group, an arylthio group, a heterocyclylthio group, an amino group, a mono- or di-alkylamino group, a mono- or di-alkanoylamino group, a mono- or di-alkoxycarbonylamino group, a mono- or di-arylcarbonylamino group, an alkylsulfinylamino group, an alkylsulfonylamino group, an arylsulfinylamino group, an arylsulfonylamino group, a carbamoyl group, a mono- or di-alkylcarbamoyl group, a mono- or di-arylcarbamoyl group, an alkylsulfinyl group, an alkenylsulfinyl group, an alkynylsulfinyl group, a cycloalkylsulfinyl group, a cycloalkenylsulfinyl group, a cycloalkynylsulfinyl group, an arylsulfinyl group, a heterocyclylsulfinyl group, an alkylsulfonyl group, an alkenylsulfonyl group, an alkynylsulfonyl group, a

cycloalkylsulfonyl group, a cycloalkenylsulfonyl group, a cycloalkynylsulfonyl group, an arylsulfonyl group, and a heterocyclylsulfonyl group wherein each substituent may optionally be further substituted by these substituents.

Examples of the optionally substituted unsaturated fused heterobicyclic ring of the present invention include an unsaturated fused heterobicyclic ring which may optionally be substituted by 1-5 substituents selected from the group consisting of a halogen atom, a nitro group, a cyano group, an oxo group, a hydroxy group, a mercapto group, a carboxyl group, a sulfo group, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkylidene- methyl group, a cycloalkenyl group, a cycloalkynyl group, an aryl group, a heterocyclyl group, an alkoxy group, an alkenyloxy group, an alkynyloxy group, a cycloalkyloxy group, a cycloalkenyloxy group, a cycloalkynyloxy group, an aryloxy group, a heterocyclyloxy group, an alkanoyl group, an alkenylcarbonyl group, an alkynylcarbonyl group, a cycloalkylcarbonyl group, a cycloalkenyl- carbonyl group, a cycloalkynyl- carbonyl group, an arylcarbonyl group, a heterocyclylcarbonyl group, an alkoxy carbonyl group, an alkenyloxy carbonyl group, an alkynyloxy- carbonyl group, a cycloalkyloxy carbonyl group, a cycloalkenyloxy- carbonyl group, a cycloalkynyloxy carbonyl group, an aryloxy carbonyl group, a heterocyclyloxy carbonyl group, an alkanoyloxy group, an alkenylcarbonyloxy group, an alkynylcarbonyloxy group, a cyclo- alkylcarbonyloxy group, a cycloalkenylcarbonyloxy group, a cyclo- alkynylcarbonyloxy group, an arylcarbonyloxy group, a heterocyclyl- carbonyloxy group, an alkylthio group, an alkenylthio group, an alkynylthio group, a cycloalkylthio group, a cycloalkenylthio group, a cycloalkynylthio group, an arylthio group, a heterocyclylthio group, an amino group, a mono- or di-alkylamino group, a mono- or di-alkanoyl- amino group, a mono- or di-alkoxy carbonylamino group, a mono- or di-arylcarbonylamino group, an alkylsulfinylamino group, an alkyl- sulfonylamino group, an arylsulfinylamino group, an arylsulfonylamino group, a carbamoyl group, a mono- or di-alkylcarbamoyl group, a mono- or di- arylcarbamoyl group, an alkylsulfinyl group, an alkenylsulfinyl group, an alkynylsulfinyl group, a cycloalkylsulfinyl group, a cyclo- alkenylsulfinyl group, a cycloalkynylsulfinyl group, an arylsulfinyl group, a heterocyclylsulfinyl group, an

alkylsulfonyl group, an alkenylsulfonyl group, an alkynylsulfonyl group, a cycloalkylsulfonyl group, a cyclo- alkenylsulfonyl group, a cycloalkynylsulfonyl group, an arylsulfonyl group, and a heterocyclylsulfonyl group, wherein each substituent may optionally be further substituted by these substituents.

5 Examples of the optionally substituted benzene ring of the present invention include a benzene ring which may optionally be substituted by 1-5 substituents selected from the group consisting of a halogen atom, a nitro group, a cyano group, a hydroxy group, a mercapto group, a carboxyl group, a sulfo group, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl
10 group, a cycloalkylidenemethyl group, a cycloalkenyl group, a cycloalkynyl group, an aryl group, a heterocyclyl group, an alkoxy group, an alkenyloxy group, an alkynyloxy group, a cycloalkyloxy group, a cycloalkenyloxy group, a cycloalkynyloxy group, an aryloxy group, a heterocyclyloxy group, an alkanoyl group, an alkenylcarbonyl group, an alkynylcarbonyl group, a
15 cycloalkylcarbonyl group, a cycloalkenylcarbonyl group, a cycloalkynylcarbonyl group, an arylcarbonyl group, a heterocyclylcarbonyl group, an alkoxycarbonyl group, an alkenyloxycarbonyl group, an alkynyloxycarbonyl group, a cycloalkyloxycarbonyl group, a cycloalkenyloxycarbonyl group, a cycloalkynyl-oxycarbonyl group, an aryloxycarbonyl group, a heterocyclyloxycarbonyl group,
20 an alkanoyloxy group, an alkenylcarbonyloxy group, an alkynylcarbonyloxy group, a cycloalkylcarbonyloxy group, a cycloalkenylcarbonyloxy group, a cycloalkynylcarbonyloxy group, an arylcarbonyloxy group, a heterocyclylcarbonyloxy group, an alkylthio group, an alkenylthio group, an alkynylthio group, a cycloalkylthio group, a cycloalkenylthio group, a
25 cycloalkynylthio group, an arylthio group, a heterocyclylthio group, an amino group, a mono- or di-alkylamino group, a mono- or di-alkanoylamino group, a mono- or di-alkoxycarbonylamino group, a mono- or di-arylcarbonylamino group, an alkylsulfinylamino group, an alkylsulfonylamino group, an arylsulfinylamino group, an arylsulfonylamino group, a carbamoyl group, a
30 mono- or di-alkylcarbamoyl group, a mono- or di-arylcarbamoyl group, an alkylsulfinyl group, an alkenylsulfinyl group, an alkynylsulfinyl group, a cycloalkylsulfinyl group, a cycloalkenylsulfinyl group, a cycloalkynylsulfinyl group, an arylsulfinyl group, a heterocyclylsulfinyl group, an alkylsulfonyl group,

an alkenylsulfonyl group, an alkynylsulfonyl group, a cycloalkylsulfonyl group, a cycloalkenylsulfonyl group, a cycloalkynylsulfonyl group, an arylsulfonyl group, a heterocyclylsulfonyl group, an alkylene group, an alkyleneoxy group, an alkylenedioxy group, and an alkenylene group wherein each substituent may optionally be further substituted by these substituents. Moreover, examples of the optionally substituted benzene ring include a benzene ring substituted with an alkylene group to form an annelated carbocycle together with the carbon atoms to which they are attached, and also includes a benzene ring substituted with an alkenylene group to form an annelated carbocycle such as a fused benzene ring together with the carbon atoms to which they are attached.

Preferable examples of the optionally substituted unsaturated monocyclic heterocyclic ring include an unsaturated monocyclic heterocyclic ring which may optionally be substituted by 1-3 substituents selected from the group consisting of a halogen atom, a hydroxy group, an alkoxy group, an alkyl group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, an alkoxyalkyl group, an alkoxyalkoxy group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkylidenemethyl group, a cycloalkenyl group, a cycloalkyloxy group, an aryl group, an aryloxy group, an arylalkoxy group, a cyano group, a nitro group, an amino group, a mono- or di-alkylamino group, an alkanoylamino group, an alkoxycarbonylamino group, a carboxyl group, an alkoxycarbonyl group, a carbamoyl group, a mono- or di-alkylcarbamoyl group, an alkanoyl group, an alkylsulfonylamino group, an arylsulfonylamino group, an alkylsulfinyl group, an alkylsulfonyl group, an arylsulfonyl group, a heterocyclyl group, and an oxo group.

Preferable examples of the optionally substituted unsaturated fused heterobicyclic ring include an unsaturated fused heterobicyclic ring which may optionally be substituted by 1-3 substituents independently selected from the group consisting of a halogen atom, a hydroxy group, an alkoxy group, an alkyl group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, an alkoxyalkyl group, an alkoxyalkoxy group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkylidenemethyl group, a cycloalkenyl group, a cycloalkyloxy group, an aryl group, an aryloxy group, an arylalkoxy group, a cyano group, a nitro group, an amino group, a mono- or di-alkylamino group, an

alkanoylamino group, an alkoxycarbonylamino group, a carboxyl group, an
alkoxycarbonyl group, a carbamoyl group, a mono- or di-alkylcarbamoyl group,
an alkanoyl group, an alkylsulfonylamino group, an arylsulfonylamino group, an
alkylsulfinyl group, an alkylsulfonyl group, an arylsulfonyl group, a heterocyclyl
5 group, and an oxo group.

Preferable examples of the optionally substituted benzene ring include a
benzene ring which may optionally be substituted by 1-3 substituents selected
from the group consisting of a halogen atom, a hydroxy group, an alkoxy group,
an alkyl group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, an
10 alkoxyalkyl group, an alkoxyalkoxy group, an alkenyl group, an alkynyl group, a
cycloalkyl group, a cycloalkylidenemethyl group, a cycloalkenyl group, a
cycloalkyloxy group, an aryl group, an aryloxy group, an arylalkoxy group, a
cyano group, a nitro group, an amino group, a mono- or di-alkylamino group, an
alkanoylamino group, an alkoxycarbonylamino group, a carboxyl group, an
15 alkoxycarbonyl group, a carbamoyl group, a mono- or di-alkylcarbamoyl group,
an alkanoyl group, an alkylsulfonylamino group, an arylsulfonylamino group, an
alkylsulfinyl group, an alkylsulfonyl group, an arylsulfonyl group, a heterocyclyl
group, an alkylene group, an alkyleneoxy group, an alkylenedioxy group, and
an alkenylene group.

20 Preferrably, the optionally substituted unsaturated monocyclic
heterocyclic ring is an unsaturated monocyclic heterocyclic ring which may
optionally be substituted by 1-3 substituents, independently selected from the
group consisting of a halogen atom, a hydroxy group, a cyano group, a nitro
group, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a
25 cycloalkylidenemethyl group, an alkoxy group, an alkanoyl group, an alkylthio
group, an alkylsulfonyl group, an alkylsulfinyl group, an amino group, a mono-
or di-alkylamino group, an alkanoylamino group, an alkoxycarbonylamino
group, a sulfamoyl group, a mono- or di-alkylsulfamoyl group, a carboxyl group,
an alkoxycarbonyl group, a carbamoyl group, a mono- or di-alkylcarbamoyl
30 group, an alkylsulfonylamino group, a phenyl group, a phenoxy group, a
phenylsulfonylamino group, a phenylsulfonyl group, a heterocyclyl group, and
an oxo group;

the optionally substituted unsaturated fused heterobicyclic ring is an unsaturated fused heterobicyclic ring which may optionally be substituted by 1-3 substituents selected from the group consisting of a halogen atom, a hydroxy group, a cyano group, a nitro group, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkylidenemethyl group, an alkoxy group, an alkylthio group, an alkylsulfonyl group, an alkylsulfinyl group, an amino group, a mono- or di-alkylamino group, an alkanoylamino group, an alkoxycarbonylamino group, a sulfamoyl group, a mono- or di-alkyl- sulfamoyl group, a carboxyl group, an alkoxycarbonyl group, a carbamoyl group, a mono- or di-alkylcarbamoyl group, an alkanoyl group, an alkylsulfonylamino group, a phenyl group, a phenoxy group, a phenylsulfonylamino group, phenylsulfonyl group, a heterocyclyl group, and an oxo group; and

the optionally substituted benzene ring is a benzene ring which may optionally be substituted by 1-3 substituents, independently selected from the group consisting of a halogen atom, a hydroxy group, a cyano group, a nitro group, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkylidenemethyl group, an alkoxy group, an alkanoyl group, an alkylthio group, an alkylsulfonyl group, an alkylsulfinyl group, an amino group, a mono- or di-alkylamino group, an alkanoylamino group, an alkoxycarbonylamino group, a sulfamoyl group, a mono- or di-alkylsulfamoyl group, a carboxyl group, an alkoxycarbonyl group, a carbamoyl group, a mono- or di-alkylcarbamoyl group, an alkylsulfonylamino group, a phenyl group, a phenoxy group, a phenylsulfonylamino group, a phenylsulfonyl group, a heterocyclyl group, an alkylene group, and an alkenylene group;

wherein each of the above-mentioned substituents on the unsaturated monocyclic heterocyclic ring, the unsaturated fused heterobicyclic ring and the benzene ring may further be substituted by 1-3 substituents, independently selected from the group consisting of a halogen atom, a hydroxy group, a cyano group, an alkyl group, a haloalkyl group, an alkoxy group, a haloalkoxy group, an alkanoyl group, an alkylthio group, an alkylsulfonyl group, a mono- or di-alkylamino group, a carboxyl group, an alkoxycarbonyl group, a phenyl group, an alkyleneoxy group, an alkylenedioxy group, an oxo group, a carbamoyl group, and a mono- or di-alkylcarbamoyl group.

Preferably, the optionally substituted unsaturated monocyclic heterocyclic ring is an unsaturated monocyclic heterocyclic ring which may optionally be substituted by 1-3 substituents, independently selected from the group consisting of a halogen atom, a cyano group, an alkyl group, an alkoxy group, an alkanoyl group, a mono- or di-alkylamino group, an alkanoylamino group, an alkoxycarbonylamino group, a carboxyl group, an alkoxycarbonyl group, a carbamoyl group, a mono- or di-alkylcarbamoyl group, a phenyl group, a heterocyclyl group, and an oxo group;

the optionally substituted unsaturated fused heterobicyclic ring is an unsaturated fused heterobicyclic ring which may optionally be substituted by 1-3 substituents independently selected from the group consisting of a halogen atom, a cyano group, an alkyl group, an alkoxy group, an alkanoyl group, a mono- or di-alkylamino group, an alkanoylamino group, an alkoxycarbonylamino group, a carboxyl group, an alkoxycarbonyl group, a carbamoyl group, a mono- or di-alkylcarbamoyl group, a phenyl group, a heterocyclyl group, and an oxo group; and

the optionally substituted benzene ring is a benzene ring which may optionally be substituted by 1-3 substituents, independently selected from the group consisting of a halogen atom, a cyano group, an alkyl group, an alkoxy group, an alkanoyl group, a mono- or di-alkylamino group, an alkanoylamino group, an alkoxycarbonylamino group, a carboxyl group, an alkoxycarbonyl group, a carbamoyl group, a mono- or di-alkylcarbamoyl group, a phenyl group, a heterocyclyl group, an alkylene group, and an alkenylene group;

wherein each of the above-mentioned substituents on the unsaturated monocyclic heterocyclic ring, the unsaturated fused heterobicyclic ring and the benzene ring may further be substituted by 1-3 substituents, independently selected from the group consisting of a halogen atom, a cyano group, an alkyl group, a haloalkyl group, an alkoxy group, a haloalkoxy group, an alkanoyl group, a mono- or di-alkylamino group, a carboxyl group, a hydroxy group, a phenyl group, an alkylendioxy group, an alkyleneoxy group, an alkoxycarbonyl group, a carbamoyl group and a mono- or di-alkylcarbamoyl group.

In a preferred embodiment of the present invention, in the compound of formula (I),

(1) Ring A is an unsaturated monocyclic heterocyclic ring which may optionally be substituted by 1-3 substituents, independently selected from the group consisting of a halogen atom, a hydroxy group, a cyano group, a nitro group, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkylidenemethyl group, an alkoxy group, an alkanoyl group, an alkylthio group, an alkylsulfonyl group, an alkylsulfinyl group, an amino group, a mono- or di-alkylamino group, a sulfamoyl group, a mono- or di-alkylsulfamoyl group, a carboxyl group, an alkoxycarbonyl group, a carbamoyl group, a mono- or di-alkylcarbamoyl group, an alkylsufonylamino group, a phenyl group, a phenoxy group, a phenylsulfonylamino group, a phenylsulfonyl group, a heterocyclyl group, and an oxo group, and

Ring B is an unsaturated monocyclic heterocyclic ring, an unsaturated fused heterobicyclic ring, or a benzene ring, each of which may optionally be substituted by 1-3 substituents, independently selected from the group consisting of a halogen atom, a hydroxy group, a cyano group, a nitro group, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkylidenemethyl group, an alkoxy group, an alkanoyl group, an alkylthio group, an alkylsulfonyl group, an alkylsulfinyl group, an amino group, a mono- or di-alkylamino group, a sulfamoyl group, a mono- or di-alkylsulfamoyl group, a carboxyl group, an alkoxycarbonyl group, a carbamoyl group, a mono- or di-alkylcarbamoyl group, an alkylsufonylamino group, a phenyl group, a phenoxy group, a phenylsulfonylamino group, a phenylsulfonyl group, a heterocyclyl group, an alkylene group, and an alkenylene group;

(2) Ring A is a benzene ring which may optionally be substituted by 1-3 substituents, independently selected from the group consisting of a halogen atom, a hydroxy group, a cyano group, a nitro group, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkylidenemethyl group, an alkoxy group, an alkanoyl group, an alkylthio group, an alkylsulfonyl group, an alkylsulfinyl group, an amino group, a mono- or di-alkylamino group, an alkanoylamino group, a sulfamoyl group, a mono- or di-alkylsulfamoyl group, a carboxyl group, an alkoxycarbonyl group, a carbamoyl group, a mono- or di-alkylcarbamoyl group, an alkylsufonylamino group, a phenyl group, a phenoxy

group, a phenylsulfonylamino group, a phenylsulfonyl group, a heterocyclyl group, an alkylene group, and an alkenylene group, and

Ring B is an unsaturated monocyclic heterocyclic ring or an unsaturated fused heterobicyclic ring, each of which may optionally be substituted by 1-3 substituents, independently selected from the group consisting of a halogen atom, a hydroxy group, a cyano group, a nitro group, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkylidenemethyl group, an alkoxy group, an alkanoyl group, an alkylthio group, an alkylsulfonyl group, an alkylsulfinyl group, an amino group, a mono- or di-alkylamino group, a sulfamoyl group, a mono- or di-alkylsulfamoyl group, a carboxyl group, an alkoxycarbonyl group, a carbamoyl group, a mono- or di-alkylcarbamoyl group, an alkylsulfonylamino group, a phenyl group, a phenoxy group, a phenylsulfonylamino group, a phenylsulfonyl group, a heterocyclyl group, an alkylene group and an oxo group; or

(3) Ring A is an unsaturated fused heterobicyclic ring which may optionally be substituted by 1-3 substituents, independently selected from the group consisting of a halogen atom, a hydroxy group, a cyano group, a nitro group, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkylidenemethyl group, an alkoxy group, an alkanoyl group, an alkylthio group, an alkylsulfonyl group, an alkylsulfinyl group, an amino group, a mono- or di-alkylamino group, a sulfamoyl group, a mono- or di-alkylsulfamoyl group, a carboxyl group, an alkoxycarbonyl group, a carbamoyl group, a mono- or di-alkylcarbamoyl group, an alkylsulfonylamino group, a phenyl group, a phenoxy group, a phenylsulfonylamino group, a phenylsulfonyl group, a heterocyclyl group, and an oxo group, and

Ring B is an unsaturated monocyclic heterocyclic ring, an unsaturated fused heterobicyclic ring, or a benzene ring, each of which may optionally be substituted by 1-3 substituents, independently selected from the group consisting of a halogen atom, a hydroxy group, a cyano group, a nitro group, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkylidenemethyl group, an alkoxy group, an alkanoyl group, an alkylthio group, an alkylsulfonyl group, an alkylsulfinyl group, an amino group, a mono- or di-alkylamino group, a sulfamoyl group, a mono- or di-alkylsulfamoyl group, a

carboxyl group, an alkoxycarbonyl group, a carbamoyl group, a mono- or di-alkylcarbamoyl group, an alkylsufonylamino group, a phenyl group, a phenoxy group, a phenylsufonylamino group, a phenylsufonyl group, a heterocyclyl group, an alkylene group and an oxo group;

5 wherein each of the above-mentioned substituents on Ring A and Ring B may optionally be substituted by 1-3 substituents, independently selected from the group consisting of a halogen atom, a cyano group, an alkyl group, a haloalkyl group, an alkoxy group, a haloalkoxy group, an alkanoyl group, a mono- or di-alkylamino group, a carboxyl group, a hydroxy group, a phenyl
10 group, an alkylenedioxy group, an alkyleneoxy group, an alkoxycarbonyl group, a carbamoyl group and a mono- or di-alkylcarbamoyl group.

In another preferred embodiment of the present invention, in the compound of formula (I), Ring A and Ring B are

(1) Ring A is an unsaturated monocyclic heterocyclic ring which may
15 optionally be substituted by a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, or an oxo group, and Ring B is (a) a benzene ring which may optionally be substituted by a halogen atom; a cyano group; a lower alkyl group; a halo-lower alkyl group; a lower alkoxy group; a halo-lower alkoxy group; a mono- or di-lower alkylamino group; a phenyl group optionally
20 substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, or a mono- or di-lower alkylamino group; or a heterocyclyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, or a mono- or di-lower alkylamino group; (b) an unsaturated monocyclic heterocyclic ring
25 which may optionally be substituted by a group selected from a halogen atom, cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, a mono- or di-lower alkylamino group, a phenyl group which may be substituted with a halogen atom, cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, or a mono- or di-
30 lower alkylamino group; and a heterocyclyl group which may optionally be substituted with a group selected from a halogen atom, cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, or a mono- or di-lower alkylamino group; or (c) an unsaturated fused heterobicyclic ring which

may optionally be substituted by a group selected from a halogen atom, cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, a mono- or di-lower alkylamino group, a phenyl group which may be substituted with a halogen atom, cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, or a mono- or di-lower alkylamino group; and a heterocyclyl group which may optionally be substituted with a group selected from a halogen atom, cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, or a mono- or di-lower alkylamino group;

- 10 (2) Ring A is a benzene ring which may optionally be substituted by a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a phenyl group, or a lower alkenylene group, and Ring B is (a) an unsaturated monocyclic heterocyclic ring which may optionally be substituted by a halogen atom; a cyano group; a lower alkyl group; a halo-lower alkyl group; a phenyl-lower alkyl group; a lower alkoxy group; a halo-lower alkoxy group; a mono- or di-lower alkylamino group; a phenyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a mono- or di-lower alkylamino group, or a carbamoyl group; or a heterocyclyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a mono- or di-lower alkylamino group or a carbamoyl group; (b) an unsaturated fused heterobicyclic ring which may optionally be substituted by a group selected from a halogen atom, cyano group, a lower alkyl group, a halo-lower alkyl group, a phenyl-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, a mono- or di-lower alkylamino group, a phenyl group which may be substituted with a halogen atom, cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, or a mono- or di-lower alkylamino group; and a heterocyclyl group which may optionally be substituted with a group selected from a halogen atom, cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, or a mono- or di-lower alkylamino group; or

(3) Ring A is an unsaturated fused heterobicyclic ring which may optionally be substituted by a halogen atom, a lower alkyl group, a halo-lower

alkyl group, a lower alkoxy group, or an oxo group, and Ring B is (a) a benzene ring which may optionally be substituted by a group selected from a halogen atom, cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, a mono- or di-lower alkylamino group, a phenyl group which may be substituted with a halogen atom, cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, or a mono- or di-lower alkylamino group; and a heterocyclyl group which may optionally be substituted with a group selected from a halogen atom, cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, or a mono- or di-lower alkylamino group; (b) an unsaturated monocyclic heterocyclic ring which may optionally be substituted by a halogen atom; a cyano group; a lower alkyl group; a halo-lower alkyl group; a lower alkoxy group; a halo-lower alkoxy group; a mono- or di-lower alkylamino group; a phenyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, or a mono- or di-lower alkylamino group; or a heterocyclyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, or a mono- or di-lower alkylamino group; or (c) an unsaturated fused heterobicyclic ring which may optionally be substituted by a group selected from a halogen atom, cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, a mono- or di-lower alkylamino group, a phenyl group which may be substituted with a halogen atom, cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, or a mono- or di-lower alkylamino group; and a heterocyclyl group which may optionally be substituted with a group selected from a halogen atom, cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, or a mono- or di-lower alkylamino group.

In another preferred embodiment, in the compound of formula (I), Y is -CH₂- and is linked at the 3-position of Ring A, with respect to X being the 1-position, Ring A is a benzene ring which is substituted by 1-3 substituents selected from the group consisting of a lower alkyl group, a halo-lower alkyl group, a halogen atom, a lower alkoxy group, a phenyl group, and a lower alkenylene group, and Ring B is an unsaturated monocyclic heterocyclic ring or

an unsaturated fused heterobicyclic ring, each of which may be substituted by 1-3 substituents selected from the group consisting of a lower alkyl group, a halo-lower alkyl group, a phenyl-lower alkyl group, a halogen atom, a lower alkoxy group, a halo-lower alkoxy group, a phenyl group, a halophenyl group, a cyanophenyl group, a lower alkylphenyl group, a halo-lower alkylphenyl group, a lower alkoxyphenyl group, a halo-lower alkoxy phenyl group, a lower alkylendioxyphenyl group, a lower alkyleneoxy phenyl group, a mono- or di-lower alkylaminophenyl group, a carbamoyl phenyl group, a mono- or di-lower alkylcarbamoylphenyl group, a heterocyclyl group, a haloheterocyclyl group, a cyanoheterocyclyl group, a lower alkylheterocyclyl group, a lower alkoxyheterocyclyl group, a mono- or di-lower alkylaminoheterocyclyl group, a carbamoylheterocyclyl group, and a mono- or di-lower alkylcarbamoyl group.

In another more preferable embodiment, in the compound of formula (I), Y is $-\text{CH}_2-$ and is linked at the 3-position of Ring A, with respect to X being the 1-position, Ring A is an unsaturated monocyclic heterocyclic ring which may be substituted by 1-3 substituents selected from the group consisting of a lower alkyl group, a halogen atom, a lower alkoxy group, and an oxo group, and Ring B is a benzene ring which may be substituted by 1-3 substituents selected from the group consisting of a lower alkyl group, a halo-lower alkyl group, a halogen atom, a lower alkoxy group, a halo-lower alkoxy group, a phenyl group, a halophenyl group, a cyanophenyl group, a lower alkylphenyl group, a halo-lower alkylphenyl group, a lower alkoxyphenyl group, a heterocyclyl group, a haloheterocyclyl group, a cyanoheterocyclyl group, a lower alkylheterocyclyl group, and a lower alkoxyheterocyclyl group.

Further, in another preferable embodiment, in the compound of formula (I), Y is $-\text{CH}_2-$ and is linked at the 3-position of Ring A, with respect to X being the 1-position, Ring A is an unsaturated monocyclic heterocyclic ring which may be substituted by 1-3 substituents selected from the group consisting of a lower alkyl group, a halogen atom, a lower alkoxy group, and an oxo group, and Ring B is an unsaturated monocyclic heterocyclic ring or an unsaturated fused heterobicyclic ring, each of which may be substituted by 1-3 substituents selected from the group consisting of a lower alkyl group, a halo-lower alkyl group, a halogen atom, a lower alkoxy group, a halo-lower alkoxy group, a

phenyl group, a halophenyl group, a cyanophenyl group, a lower alkylphenyl group, a halo-lower alkylphenyl group, a lower alkoxyphenyl group, a halo-lower alkoxyphenyl group, a heterocyclyl group, a haloheterocyclyl group, a cyanoheterocyclyl group, a lower alkylheterocyclyl group, and a lower
5 alkoxyheterocyclyl group. In a more preferable embodiment of the present invention, X is a carbon atom and Y is -CH₂-.

Further, in another preferable embodiment, in the compound of formula (I), Ring A and Ring B are

(1) Ring A is a benzene ring which may optionally be substituted by 1-3
10 substituents, independently selected from the group consisting of a halogen atom, a lower alkyl group optionally substituted by a halogen atom or a lower alkoxy group, a lower alkoxy group optionally substituted by a halogen atom or a lower alkoxy group, a cycloalkyl group, a cycloalkoxy group, a phenyl group, and a lower alkenylene group, and

15 Ring B is an unsaturated monocyclic heterocyclic ring or an unsaturated fused heterobicyclic ring, each of which may optionally be substituted by 1-3 substituents, independently selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted by a halogen atom, a lower alkoxy group or a phenyl group; a lower alkoxy group optionally substituted by
20 a halogen atom or a lower alkoxy group; a cycloalkyl group; a cycloalkoxy group; a phenyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, or a carbamoyl group; a heterocyclyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl
25 group, a lower alkoxy group, a halo-lower alkoxy group or a carbamoyl group; and an oxo group,

(2) Ring A is an unsaturated monocyclic heterocyclic ring which may optionally be substituted by 1-3 substituents, independently selected from the group consisting of a halogen atom, a lower alkyl group optionally substituted
30 by a lower alkoxy group, a lower alkoxy group optionally substituted by a halogen atom or a lower alkoxy group, a cycloalkyl group, a cycloalkoxy group, and an oxo group, and

Ring B is a benzene ring which may optionally be substituted by 1-3 substituents, independently selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted by a halogen atom, a lower alkoxy group or a phenyl group; a lower alkoxy group optionally substituted by
5 a halogen atom or a lower alkoxy group; a cycloalkyl group; a cycloalkoxy group; a phenyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group or a halo-lower alkoxy group; a heterocyclyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower
10 alkoxy group or a halo-lower alkoxy group; a lower alkylene group,

(3) Ring A is an unsaturated monocyclic heterocyclic ring which may optionally be substituted by 1-3 substituents, independently selected from the group consisting of a halogen atom, a lower alkyl group optionally substituted by a halogen atom or a lower alkoxy group, a lower alkoxy group optionally
15 substituted by a halogen atom or a lower alkoxy group, a cycloalkyl group, a cycloalkoxy group, and an oxo group,

Ring B is an unsaturated monocyclic heterocyclic ring or an unsaturated fused heterobicyclic ring, each of which may optionally be substituted by 1-3 substituents, independently selected from the group consisting of a halogen
20 atom; a lower alkyl group optionally substituted by a halogen atom, a lower alkoxy group or a phenyl group; a lower alkoxy group optionally substituted by a halogen atom or a lower alkoxy group; a cycloalkyl group; a cycloalkoxy group; a phenyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group or a halo-lower alkoxy group; a heterocyclyl group optionally substituted by a halogen
25 atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group or a halo-lower alkoxy group; and an oxo group;

(4) Ring A is an unsaturated fused heterobicyclic ring which may optionally be substituted by 1-3 substituents, independently selected from the group consisting of a halogen atom, a lower alkyl group optionally substituted
30 by a lower alkoxy group, a lower alkoxy group optionally substituted by a halogen atom or a lower alkoxy group, a cycloalkyl group, a cycloalkoxy group, and an oxo group,

Ring B is a benzene ring which may optionally be substituted by 1-3 substituents, independently selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted by a halogen atom, a lower alkoxy group or a phenyl group; a lower alkoxy group optionally substituted by
5 a halogen atom or a lower alkoxy group; a cycloalkyl group; a cycloalkoxy group; a phenyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group or a halo-lower alkoxy group; a heterocyclyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower
10 alkoxy group or a halo-lower alkoxy group; and a lower alkylene group, or

(5) Ring A is an unsaturated monocyclic heterocyclic ring which may optionally be substituted by 1-3 substituents, independently selected from the group consisting of a halogen atom, a lower alkyl group optionally substituted by a lower alkoxy group, a lower alkoxy group optionally substituted by a
15 halogen atom or a lower alkoxy group, a cycloalkyl group, a cycloalkoxy group, and an oxo group,

Ring B is an unsaturated monocyclic heterocyclic ring or an unsaturated fused heterobicyclic ring, each of which may optionally be substituted by 1-3 substituents, independently selected from the group consisting of a halogen
20 atom; a lower alkyl group optionally substituted by a halogen atom, a lower alkoxy group or a phenyl group; a lower alkoxy group optionally substituted by a halogen atom or a lower alkoxy group; a cycloalkyl group; a cycloalkoxy group; a phenyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group or a halo-
25 lower alkoxy group; a heterocyclyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group or a halo-lower alkoxy group; and an oxo group.

In another preferable embodiment, in the compound of formula (I), Y is linked at the 3-position of Ring A, with respect to X being the 1-position, Ring A
30 is a benzene ring which may optionally be substituted by a halogen atom, a lower alkyl group optionally substituted by a halogen atom, a lower alkoxy group, or a phenyl group, and Ring B is an unsaturated monocyclic heterocyclic ring or an unsaturated fused heterobicyclic ring which may optionally be

substituted by 1-3 substituents, independently selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted by a halogen atom or a phenyl group; a lower alkoxy group; a phenyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, or a lower alkoxy group; a heterocyclyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, or a lower alkoxy group; and an oxo group.

In another more preferable embodiment, in the compound of formula (I), Y is linked at the 3-position of Ring A, with respect to X being the 1-position, Ring A is an unsaturated monocyclic heterocyclic ring which may optionally be substituted by a substituent selected from a halogen atom, a lower alkyl group, and an oxo group, and Ring B is a benzene ring which may optionally be substituted by a substituent selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted by a halogen atom or a phenyl group; a lower alkoxy group; a phenyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, or a lower alkoxy group; a heterocyclyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, or a lower alkoxy group; and a lower alkylene group.

Preferable examples of unsaturated monocyclic heterocyclic ring include a 5- or 6-membered unsaturated heterocyclic ring containing 1 or 2 hetero atoms independently selected from a nitrogen atom, an oxygen atom, and a sulfur atom. More specifically, preferred are furan, thiophene, oxazole, isoxazole, triazole, tetrazole, pyrazole, pyridine, pyrimidine, pyrazine, dihydroisoxazole, dihydropyridine, and thiazole. Preferable unsaturated fused heterobicyclic ring includes a 9- or 10-membered unsaturated fused heterocyclic ring containing 1 to 4 heteroatoms independently selected from a nitrogen atom, an oxygen atom, and a sulfur atom. More specifically, preferred are indoline, isoindoline, benzothiazole, benzoxazole, indole, indazole, quinoline, isoquinoline, benzothiophene, benzofuran, thienothiophene, and dihydroisoquinoline.


In a more preferred embodiment, in the compound of formula (I), Ring A is a benzene ring which may optionally be substituted by a substituent

selected from the group consisting of a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, and a phenyl group, and Ring B is a heterocyclic ring selected from the group consisting of thiophene, furan, benzofuran, benzothiophene, and benzothiazole, wherein the heterocyclic ring
5 may optionally be substituted by a substituent selected from the following group: a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a phenyl-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, a phenyl group, a halophenyl group, a lower alkylphenyl group, a lower alkoxyphenyl group, a thienyl group, a halothienyl group, a pyridyl group, a
10 halopyridyl group, and a thiazolyl group.

In yet another preferred embodiment, in the compound of formula (I), Y is $-CH_2-$, Ring A is an unsaturated monocyclic heterocyclic ring or an unsaturated fused heterobicyclic ring selected from the group consisting of thiophene, dihydroisoquinoline, dihydroisoxazole, triazole, pyrazole,
15 dihydropyridine, dihydroindole, indole, indazole, pyridine, pyrimidine, pyrazine, quinoline, and a isoindoline, wherein the heterocyclic ring may optionally be substituted by a substituent selected from the following group: a halogen atom, a lower alkyl group, and an oxo group, and Ring B is a benzene ring which may optionally be substituted by a substituent selected from the following group: a
20 halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, and a halo-lower alkoxy group.


In a further preferred embodiment, in the compound of formula (I), Ring A is a benzene ring which is substituted by a halogen atom or a lower alkyl group, and Ring B is thienyl group which is substituted by phenyl group or a
25 heterocyclyl group in which said phenyl group and heterocyclyl group is substituted by 1-3 substituents selected from a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, and a halo-lower alkoxy group.

Further, in another aspect of the present invention, preferable examples
30 of the compound of the formula (I) include a compound wherein Ring A is



wherein R^{1a} , R^{2a} , R^{3a} , R^{1b} , R^{2b} , and R^{3b} are each independently a hydrogen atom, a halogen atom, a hydroxy group, an alkoxy group, an alkyl group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, an alkoxyalkyl group, an alkoxyalkoxy group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkylidenemethyl group, a cycloalkenyl group, a cycloalkyloxy group, a phenyl group, a phenylalkoxy group, a cyano group, a nitro group, an amino group, a mono- or di-alkylamino group, an alkanoylamino group, a carboxyl group, an alkoxycarbonyl group, a carbamoyl group, a mono- or di-alkylcarbamoyl group, an alkanoyl group, an alkylsulfonylamino group, a phenylsulfonylamino group, an alkylsulfinyl group, an alkylsulfonyl group, or a phenylsulfonyl group, and

Ring B is



wherein R^{4a} and R^{5a} are each independently a hydrogen atom; a halogen atom; a hydroxy group; an alkoxy group; an alkyl group; a haloalkyl group; a haloalkoxy group; a hydroxyalkyl group; an alkoxyalkyl group; a phenylalkyl group; an alkoxyalkoxy group; a hydroxyalkoxy group; an alkenyl group; an alkynyl group; a cycloalkyl group; a cycloalkylidenemethyl group; a cycloalkenyl group; a cycloalkyloxy group; a phenyloxy group; a phenylalkoxy group; a cyano group; a nitro group; an amino group; a mono- or di-alkylamino group; an alkanoylamino group; a carboxyl group; an alkoxycarbonyl group; a carbamoyl group; a mono- or di-alkylcarbamoyl group; an alkanoyl group; an alkylsulfonylamino group; a phenylsulfonylamino group; an alkylsulfinyl group; an alkylsulfonyl group; a phenylsulfonyl group; a phenyl group optionally substituted by a halogen atom, a cyano group, an alkyl group, a haloalkyl group, an alkoxy group, a haloalkoxy group, an alkylenedioxy group, an alkyleneoxy group, a mono- or di-alkylamino group, a carbamoyl group, or a

mono- or di-alkylcarbamoyl group; or a heterocyclyl group optionally substituted by a halogen atom, a cyano group, an alkyl group, a haloalkyl group, an alkoxy group, a haloalkoxy group, a carbamoyl group, or a mono- or di-alkylcarbamoyl group, or R^{4a} and R^{5a} are bonded to each other at the terminals thereof to form an alkylene group; and

R^{4b}, R^{5b}, R^{4c} and R^{5c} are each independently a hydrogen atom; a halogen atom; a hydroxy group; an alkoxy group; an alkyl group; a haloalkyl group; a haloalkoxy group; a hydroxyalkyl group; an alkoxyalkyl group; a phenylalkyl group; an alkoxyalkoxy group; a hydroxyalkoxy group; an alkenyl group; an alkynyl group; a cycloalkyl group; a cycloalkylidenemethyl group; a cycloalkenyl group; a cycloalkyloxy group; a phenyloxy group; a phenylalkoxy group; a cyano group; a nitro group; an amino group; a mono- or di-alkylamino group; an alkanoylamino group; a carboxyl group; an alkoxycarbonyl group; a carbamoyl group; a mono- or di-alkylcarbamoyl group; an alkanoyl group; an alkylsulfonylamino group; a phenylsulfonylamino group; an alkylsulfinyl group; an alkylsulfonyl group; a phenylsulfonyl group; a phenyl group optionally substituted by a halogen atom, a cyano group, an alkyl group, a haloalkyl group, an alkoxy group, a haloalkoxy group, a methylenedioxy group, an ethyleneoxy group, or a mono- or di-alkylamino group; or a heterocyclyl group optionally substituted by a halogen atom, a cyano group, an alkyl group, a haloalkyl group, an alkoxy group or a haloalkoxy group.


More preferred is a compound of formula (I) wherein R^{1a}, R^{2a}, R^{3a}, R^{1b}, R^{2b}, and R^{3b} are each independently a hydrogen atom, a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, or a phenyl group;

R^{4a} and R^{5a} are each independently a hydrogen atom; a halogen atom; a lower alkyl group; a halo-lower alkyl group; a phenyl-lower alkyl group; a phenyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, a methylenedioxy group, an ethyleneoxy group, a mono- or di-lower alkylamino group, a carbamoyl group, or a mono- or di-lower alkylcarbamoyl group; or a heterocyclyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a lower alkoxy group, a carbamoyl group, or

a mono- or di-lower alkylcarbamoyl group, or R^{4a} and R^{5a} are bonded to each other at the terminals thereof to form a lower alkylene group; and

R^{4b} , R^{5b} , R^{4c} and R^{5c} are each independently a hydrogen atom, a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, or a halo-lower alkoxy group.

Further preferred is a compound of formula (I) in which Ring B is a ring of the following structure




wherein R^{4a} is a phenyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, a methylenedioxy group, an ethyleneoxy group, a mono- or di-lower alkylamino group, a carbamoyl group, or a mono- or di-lower alkylcarbamoyl group; or a heterocyclyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a lower alkoxy group, a carbamoyl group, or a mono- or di-lower alkylcarbamoyl group, and


R^{5a} is a hydrogen atom, or

R^{4a} and R^{5a} are bonded to each other at the terminals thereof to form a lower alkylene group.

Further more preferred, is a compound of formula (I) in which Ring A is



wherein R^{1a} is a halogen atom, a lower alkyl group, or a lower alkoxy group, and R^{2a} and R^{3a} are hydrogen atoms; and Ring B is




wherein R^{4a} is a phenyl group optionally substituted by a substituent selected from the group consisting of a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, a mono- or di-lower alkylamino group, a carbamoyl group, and a mono-

or di-lower alkylcarbamoyl group; or a heterocyclyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a lower alkoxy group, a carbamoyl group, or a mono- or di-lower alkylcarbamoyl group, and R^{5a} is a hydrogen atom, and Y is $-\text{CH}_2-$.

5 In more preferable embodiment, in the compound of formula (I), R^{4a} is a phenyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, or a halo-lower alkoxy group; or a heterocyclyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, or a lower alkoxy group.


10 In another embodiment, a preferable compound of formula (I) can be represented by the following formula (IA):



wherein R^A is a halogen atom, a lower alkyl group or a lower alkoxy group; R^B is a phenyl group optionally substituted by 1-3 substituents selected from a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, a methylenedioxy group, an ethyleneoxy group, a mono- or di-lower alkylamino group, a carbamoyl group, and a mono- or di-lower alkylcarbamoyl group; or a heterocyclyl group optionally substituted by 1-3 substituents selected from a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, a mono- or di-lower alkylamino group, a carbamoyl group, and a mono- or di-lower alkylcarbamoyl group; and R^C is hydrogen atom; or R^B and R^C taken together are a fused benzene ring which may be substituted by a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group or a halo-lower alkoxy group.

In a preferable embodiment, in the compound of formula (I), R^A is a halogen atom or a lower alkyl group, R^C is hydrogen atom, and R^B is phenyl

group substituted by 1-3 substituents selected from a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, a methylenedioxy group, an ethyleneoxy group, a mono- or di-lower alkylamino group, a carbamoyl group, and a mono- or di-lower alkylcarbamoyl group; or a heterocyclyl group substituted by 1-3 substituents selected from the group consisting of a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, a mono- or di-lower alkylamino group, a carbamoyl group, and a mono- or di-lower alkylcarbamoyl group. The chemical structure of such compounds are represented by the following formula (IA'):



wherein R^A is a halogen atom, or a lower alkyl group, Ring C is a phenyl group substituted by 1-3 substituents selected from the group consisting of a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, a methylenedioxy group, an ethyleneoxy group, a mono- or di-lower alkylamino group, a carbamoyl group, and a mono- or di-lower alkylcarbamoyl group; or a heterocyclyl group substituted by 1-3 substituents selected from the group consisting of a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, a mono- or di-lower alkylamino group, a carbamoyl group, and a mono- or di-lower alkylcarbamoyl group.

In a more preferable embodiment, in the compound of formula (I), Ring C is a phenyl group substituted by 1-3 substituents selected from the group consisting of a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, and a mono- or di-lower alkylamino group; or a heterocyclyl group substituted by a substituent selected from the group consisting of a halogen atom, a cyano group, a lower


alkyl group, a halo-lower alkyl group, a lower alkoxy group, and a halo-lower alkoxy group.

Among them, a compound of formula (I) in which Ring C is a phenyl group substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group or a halo-lower alkoxy group; or a heterocyclyl group substituted by a halogen atom, a cyano group, a lower alkyl group, or a lower alkoxy group is preferred.


A preferred heterocyclyl group includes a 5- or 6-membered heterocyclyl group containing 1 or 2 hetero atoms independently selected from the group consisting of a nitrogen atom, an oxygen atom, and a sulfur atom, or a 9- or 10-membered heterocyclyl group containing 1 to 4 hetero atoms independently selected from the group consisting of a nitrogen atom, an oxygen atom, and a sulfur atom. Specifically, a thienyl group, a pyridyl group, a pyrimidyl group, a pyrazinyl group, pyrazolyl group, a thiazolyl group, a quinolyl group, a tetrazolyl group and an oxazolyl group are preferred.

In a further preferable embodiment, in the compound of formula (I), Ring C is a phenyl group substituted by a halogen atom or a cyano group, or a pyridyl group substituted by a halogen atom.

In another embodiment, preferred is a compound of formula (I), in which Ring A is




wherein R^{1a} is a halogen atom, a lower alkyl group, or a lower alkoxy group, and R^{2a} and R^{3a} are hydrogen atoms; and Ring B is




wherein R^{4b} and R^{5b} are each independently a hydrogen atom, a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, or a halo-lower alkoxy group.

In another aspect of the present invention, preferable examples of the compound of formula (I), include a compound represented by the following formula (IB):




- 5 wherein R^8 , R^9 and R^{10} are each independently a hydrogen atom, a halogen atom, a hydroxy group, an alkoxy group, an alkyl group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, an alkoxyalkyl group, an alkoxyalkoxy group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkylidenemethyl group, a cycloalkenyl group, a cycloalkyloxy group, an aryloxy group, an arylalkoxy group, a cyano group, a nitro group, an amino group, a mono- or di-alkylamino group, an alkylcarbonylamino group, a carboxyl group, an alkoxycarbonyl group, a carbamoyl group, a mono- or di-alkylcarbamoyl group, an alkanoyl group, an alkylsulfonylamino group, an arylsulfonylamino group, an alkylsulfinyl group, an alkylsulfonyl group, or an
- 10 arylsulfonyl group; and a group represented by:
- 15




- wherein R^{6a} and R^{7a} are each independently a hydrogen atom, a halogen atom, a hydroxy group, an alkoxy group, an alkyl group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, an alkoxyalkyl group, an
- 20 alkoxyalkoxy group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkylidenemethyl group, a cycloalkenyl group, a cycloalkyloxy group, an

aryloxy group, an arylalkoxy group, a cyano group, a nitro group, an amino group, a mono- or di-alkylamino group, an alkylcarbonylamino group, a carboxyl group, an alkoxycarbonyl group, a carbamoyl group, a mono- or di-alkylcarbamoyl group, an alkanoyl group, an alkylsulfonylamino group, an arylsulfonylamino group, an alkylsulfinyl group, an alkylsulfonyl group, or an arylsulfonyl group and R^{6b} and R^{7b} are each independently a hydrogen atom, a halogen atom, an alkyl group, a haloalkyl group, or an alkoxy group.

Among the compounds represented by the formula (IB), more preferred is a compound in which R^8 , R^9 and R^{10} are each independently a hydrogen atom, a halogen atom, a lower alkyl group, a cycloalkyl group, a hydroxy-lower alkyl group, a halo-lower alkyl group, a lower alkoxy-lower alkyl group, a lower alkoxy group, a cycloalkoxy group, a halo-lower alkoxy group, or a lower alkoxy-lower alkoxy group, and a group represented by:




wherein R^{6a} , R^{7a} are each independently a hydrogen atom, a halogen atom, a lower alkyl group, a cycloalkyl group, a hydroxy-lower alkyl group, a halo-lower alkyl group, a lower alkoxy-lower alkyl group, a lower alkoxy group, a cycloalkoxy group, a halo-lower alkoxy group, or a lower alkoxy-lower alkoxy group, or a group represented by:



wherein R^{6b} and R^{7b} are each independently a hydrogen atom, a halogen atom, a lower alkyl group, a halo-lower alkyl group, or a lower alkoxy group.

In another aspect, preferable examples of the compound of formula (I) include a compound represented by the following formula (IC):



wherein Ring B' is an optionally substituted benzene ring, an optionally substituted unsaturated monocyclic heterocyclic ring, or an optionally substituted unsaturated fused heterobicyclic ring.

- 5 Preferable examples of Ring B' include a benzene ring and a heterocyclic ring, both of which may have a substituent(s) selected from the group consisting of a halogen atom; a cyano group; a lower alkyl group optionally substituted by a halogen atom; a lower alkoxy group optionally substituted by a halogen atom; a lower alkanoyl group; a mono- or di-lower
- 10 alkylamino group; a lower alkoxycarbonyl group; a carbamoyl group; a mono- or di-lower alkylcarbamoyl group; a phenyl group optionally substituted by a substituent(s) selected from a halogen atom, a cyano group, a lower alkyl group optionally substituted by a halogen atom, a lower alkoxy group optionally substituted by a halogen atom, a lower alkanoyl group, a mono- or di-lower
- 15 alkylamino group, a lower alkoxycarbonyl group, a carbamoyl group, or a mono- or di-lower alkylcarbamoyl group; a heterocyclyl group optionally substituted by a substituent(s) selected from a halogen atom, a cyano group, a lower alkyl group optionally substituted by a halogen atom, a lower alkoxy group optionally substituted by a halogen atom, a lower alkanoyl group, a
- 20 mono- or di-lower alkylamino group, a lower alkoxycarbonyl group, a carbamoyl group, or a mono- or di-lower alkylcarbamoyl group; an alkylene group; and an oxo group.

- More preferable examples of Ring B' include a benzene ring which may be substituted by a substituent selected from the group consisting of a halogen
- 25 atom; a cyano group; a lower alkyl group optionally substituted by a halogen atom; a lower alkoxy group optionally substituted by a halogen atom; a mono- or di-lower alkylamino group; a phenyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group optionally substituted by a

halogen atom, a lower alkoxy group optionally substituted by a halogen atom; a heterocyclyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group optionally substituted by a halogen atom, a lower alkoxy group optionally substituted by a halogen atom.

- 5 Preferred compound of formula (I) may be selected from the group consisting of:

1-(β -D-glucopyranosyl)-4-chloro-3-(6-ethylbenzo[b]thiophen-2-ylmethyl)benzene;

- 10 1-(β -D-glucopyranosyl)-4-chloro-3-[5-(5-thiazolyl)-2-thienylmethyl]benzene;

1-(β -D-glucopyranosyl)-4-chloro-3-(5-phenyl-2-thienyl- methyl)benzene;

1-(β -D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene;

- 15 1-(β -D-glucopyranosyl)-4-chloro-3-[5-(2-pyrimidinyl)-2-thienylmethyl]benzene;

1-(β -D-glucopyranosyl)-4-methyl-3-[5-(2-pyrimidinyl)-2-thienylmethyl]benzene;

1-(β -D-glucopyranosyl)-4-chloro-3-[5-(3-cyanophenyl)-2-thienylmethyl]benzene;

- 20 1-(β -D-glucopyranosyl)-4-chloro-3-[5-(4-cyanophenyl)-2-thienylmethyl]benzene;

1-(β -D-glucopyranosyl)-4-methyl-3-[5-(6-fluoro-2-pyridyl)- 2-thienylmethyl]benzene;

- 25 1-(β -D-glucopyranosyl)-4-chloro-3-[5-(6-fluoro-2-pyridyl)- 2-thienylmethyl]benzene;

1-(β -D-glucopyranosyl)-4-methyl-3-[5-(3-difluoromethyl- phenyl)-2-thienylmethyl]benzene;

1-(β -D-glucopyranosyl)-4-methyl-3-[5-(3-cyanophenyl)-2-thienylmethyl]benzene;

- 30 1-(β -D-glucopyranosyl)-4-methyl-3-[5-(4-cyanophenyl)-2-thienylmethyl]benzene;

1-(β -D-glucopyranosyl)-4-chloro-3-[5-(6-fluoro-3-pyridyl)- 2-thienylmethyl]benzene;

1-(β -D-glucopyranosyl)-4-fluoro-3-(5-(3-cyanophenyl)-2-thienylmethyl)benzene;

a pharmaceutically acceptable salt thereof; and a prodrug thereof.

Particularly preferred compounds of formula (I) include:

5 1-(β -D-glucopyranosyl)-4-methyl-3-[5-(3-cyano-phenyl)-2-thienylmethyl]benzene, or a pharmaceutically acceptable salt thereof, or a prodrug thereof;

10 1-(β -D-glucopyranosyl)-4-methyl-3-[5-(4-cyano-phenyl)-2-thienylmethyl]benzene, or a pharmaceutically acceptable salt thereof, or a prodrug thereof;

1-(β -D-glucopyranosyl)-4-methyl-3-[5-(4-fluoro-phenyl)-2-thienylmethyl]benzene, or a pharmaceutically acceptable salt thereof, or a prodrug thereof;

15 1-(β -D-glucopyranosyl)-4-chloro-3-[5-(3-cyano-phenyl)-2-thienylmethyl]benzene, or a pharmaceutically acceptable salt thereof, or a prodrug thereof;

1-(β -D-glucopyranosyl)-4-methyl-3-[5-(6-fluoro-2-pyridyl)-2-thienylmethyl]benzene, or a pharmaceutically acceptable salt thereof, or a prodrug thereof;

20 1-(β -D-glucopyranosyl)-4-chloro-3-[5-(6-fluoro-2-pyridyl)-2-thienylmethyl]benzene, or a pharmaceutically acceptable salt thereof, or a prodrug thereof;

25 1-(β -D-glucopyranosyl)-4-chloro-3-[5-(6-fluoro-3-pyridyl)-2-thienylmethyl]benzene, or a pharmaceutically acceptable salt thereof, or a prodrug thereof; and

1-(β -D-glucopyranosyl)-4-fluoro-3-(5-(3-cyanophenyl)-2-thienylmethyl)benzene, or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

30 The pharmaceutically acceptable salt of the compounds of the formula (I) includes, for example, a salt with an alkali metal such as lithium, sodium, potassium, etc.; a salt with an alkaline earth metal such as calcium, magnesium, etc.; a salt with zinc or aluminum; a salt with an organic base such

as ammonium, choline, diethanolamine, lysine, ethylenediamine, t-butylamine, t-octylamine, tris(hydroxymethyl)aminomethane, N-methyl glucosamine, triethanolamine and dehydroabietylamine; a salt with an inorganic acid such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, etc.; or a salt with an organic acid such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, etc.; or a salt with an acidic amino acid such as aspartic acid, glutamic acid, etc.

10 The term “**prodrug**” means an ester or carbonate, which is formed by reacting one or more hydroxy groups of the compound of the formula (I) with an acylating agent substituted by an alkyl, an alkoxy or an aryl by a conventional method to produce acetate, pivalate, methylcarbonate, benzoate, etc. Further, the prodrug includes also an ester or amide, which is similarly formed by
15 reacting one or more hydroxy groups of the compound of the formula (I) with an α -amino acid or a β -amino acid, etc. using a condensing agent by a conventional method.

 The compounds of formula (I) also includes a mixture of stereoisomers, or each pure or substantially pure isomer. For example, the present compound
20 may optionally have one or more asymmetric centers at a carbon atom containing any one of substituents. Therefore, the compounds of the formula (I) may exist in the form of enantiomer or diastereomer, or a mixture thereof. When the compounds of formula (I) contains a double bond, the present compound may exist in the form of geometric isomerism (cis-compound, trans-compound), and when the compounds of formula (I) contains an unsaturated
25 bond such as carbonyl, then the present compound may exist in the form of a tautomer, and the present compound also includes these isomers or a mixture thereof. The starting compound in the form of a racemic mixture, enantiomer or diastereomer may be used in the processes for preparing the present
30 compound. When the present compound is obtained in the form of a diastereomer or enantiomer, they can be separated by a conventional method such as chromatography or fractional crystallization.

In addition, the compounds of formula (I) include an intramolecular salt, hydrate, solvate or polymorphism thereof.

The methods of the present inventions are directed to the treatment and or prevention (including delay in the progression or onset of) of "glucose-related disorders". As used herein, the term "**glucose related disorder**" shall be defined as any disorder which is characterized by or is developed as a consequence of elevated glucose levels. Glucose-related disorders shall include diabetes mellitus, diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, delayed wound healing, insulin resistance, hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids, elevated blood levels of glucose, hyperlipidemia, obesity, hypertriglyceridemia, Syndrome X, diabetic complications, atherosclerosis, or hypertension. In particular, the "glucose related-disorder" is diabetes mellitus (type 1 and type 2 diabetes mellitus, etc.), diabetic complications (such as diabetic retinopathy, diabetic neuropathy, diabetic nephropathy), obesity, or postprandial hyperglycemia.

In an embodiment of the present invention, the glucose related disorder is selected from the group consisting of diabetes mellitus, diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, delayed wound healing, insulin resistance, hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids, hyperlipidemia, obesity, hypertriglyceridemia, Syndrome X, diabetic complications, atherosclerosis and hypertension.

In another embodiment of the present invention, the glucose related disorder is selected from the group consisting of type 1 diabetes mellitus, type 2 diabetes mellitus, diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, obesity and postprandial hyperglycemia. In another embodiment of the present invention, the glucose related disorder is selected from the group consisting of type 1 diabetes mellitus, type 2 diabetes mellitus, diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, obesity, and delayed wound healing. In another embodiment of the present invention, the glucose related disorders is selected from the group consisting of poor glycemic control, Type 2 Diabetes Mellitus, Syndrome X, gestational diabetes, insulin resistance, hyperglycemia. In another embodiment of the present invention, the glucose related disorder is Type 2 diabetes mellitus.

In another embodiment, the glucose related disorder is selected from the group consisting of elevated glucose level, pre-diabetes, impaired oral glucose tolerance, poor glycemic control, Type 2 Diabetes Mellitus, Syndrome X (also known as metabolic syndrome), gestational diabetes, insulin resistance, and
5 hyperglycemia.

Treatment of glucose related disorders may comprise lowering glucose levels, improving glycemic control, decreasing insulin resistance and / or preventing the development of a glucose related disorder (for example preventing a patient suffering from impaired oral glucose tolerance or elevated
10 glucose levels from developing Type 2 diabetes mellitus).

As used herein, the terms “**Syndrome X**”, “**Metabolic Syndrome**” and “**Metabolic Syndrome X**” shall mean a disorder that presents risk factors for the development of Type 2 diabetes mellitus and cardiovascular disease and is characterized by insulin resistance and hyperinsulinemia and may be
15 accompanied by one or more of the following: (a) glucose intolerance, (b) Type 2 diabetes, (c) dyslipidemia, (d) hypertension and (e) obesity.

The term “**subject**” as used herein, refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.

20 As used herein, the term “**composition**” is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts.

As used herein, unless otherwise noted, the terms “**treating**”,
25 “**treatment**” and the like, shall include the management and care of a subject or patient (preferably mammal, more preferably human) for the purpose of combating a disease, condition, or disorder and includes the administration of a compound of the present invention to prevent the onset of the symptoms or complications, alleviate the symptoms or complications, or eliminate the
30 disease, condition, or disorder.

As used herein, unless otherwise noted, the term “**prevention**” shall include (a) reduction in the frequency of one or more symptoms; (b) reduction in the severity of one or more symptoms; (c) the delay or avoidance of the

development of additional symptoms; and / or (d) delay or avoidance of the development of the disorder or condition.

One skilled in the art will recognize that wherein the present invention is directed to methods of prevention, a subject in need of thereof (i.e. a subject in
5 need of prevention) shall include any subject or patient (preferably a mammal, more preferably a human) who has experienced or exhibited at least one symptom of the disorder, disease or condition to be prevented. Further, a subject in need thereof may additionally be a subject (preferably a mammal, more preferably a human) who has not exhibited any symptoms of the disorder,
10 disease or condition to be prevented, but who has been deemed by a physician, clinician or other medical profession to be at risk of developing said disorder, disease or condition. For example, the subject may be deemed at risk of developing a disorder, disease or condition (and therefore in need of prevention or preventive treatment) as a consequence of the subject's medical
15 history, including, but not limited to, family history, pre-disposition, co-existing (comorbid) disorders or conditions, genetic testing, and the like.

The term “**therapeutically effective amount**” as used herein, means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a
20 researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease or disorder being treated.

Wherein the present invention is directed to co-therapy or combination therapy, comprising administration of (a) metformin or a pharmaceutically acceptable salt thereof and (b) a compound of formula (I) or a pharmaceutically
25 acceptable salt thereof, “**therapeutically effective amount**” shall mean that amount of the combination of agents taken together so that the combined effect elicits the desired biological or medicinal response. For example, the therapeutically effective amount of co-therapy comprising administration of (a) metformin or a pharmaceutically acceptable salt thereof and (b) a compound of
30 formula (I) or a pharmaceutically acceptable salt thereof, would be the amount of (a) the metformin or a pharmaceutically acceptable salt thereof and (b) the compound of formula (I) or pharmaceutically acceptable salt thereof that when taken together or sequentially have a combined effect that is therapeutically

effective. Further, it will be recognized by one skilled in the art that in the case of co-therapy with a therapeutically effective amount, as in the example above, the amount of the (a) metformin or pharmaceutically acceptable salt thereof and / or the amount of the (b) compound of formula (I) or pharmaceutically

5 acceptable salt thereof individually may or may not be therapeutically effective.

One skilled in the art will further recognize that the term “**therapeutically effective amount**” of co-therapy comprising administration of (a) glyburide, and (b) a compound of formula (I) or a pharmaceutically acceptable salt thereof shall mean that amount of the glyburide and the amount of the compound of
10 formula (I) or pharmaceutically acceptable salt thereof, that when taken together or sequentially have a combined effect that is therapeutically effective; and further that the amount of each of said components individually may or may not be therapeutically effective.

One skilled in the art will further recognize that the “therapeutically
15 effective amount” of co-therapy comprising administration of (a) metformin or a pharmaceutically acceptable salt thereof, (b) a compound of formula (I) or a pharmaceutically acceptable salt thereof and (c) a sulfonylurea (preferably glyburide) or pharmaceutically acceptable salt thereof shall mean that amount of each of the components that that when taken together or sequentially have a
20 combined effect that is therapeutically effective; and further that the amount of each of the components individually may or may not be therapeutically effective.

As used herein, the terms “**co-therapy**” and “**combination therapy**” shall mean treatment of a subject in need thereof by administering (a)
25 metformin or a pharmaceutically acceptable salt thereof (b) a compound of formula (I) or pharmaceutically acceptable salt thereof and optionally (c) a sulfonylurea (preferably glyburide) or pharmaceutically acceptable salt thereof, wherein the (a) metformin or a pharmaceutically acceptable salt thereof, the (b) compound of formula (I) or pharmaceutically acceptable salt thereof and
30 optionally (c) the sulfonylurea (preferably glyburide) or pharmaceutically acceptable salt thereof are administered by any suitable means, simultaneously, sequentially, separately or in a single pharmaceutical dosage form. Where the (a) metformin or a pharmaceutically acceptable salt thereof,

the (b) compound of formula (I) or pharmaceutically acceptable salt thereof and optionally (c) the sulfonylurea (preferably glyburide) or pharmaceutically acceptable salt thereof are administered in separate dosage forms, the number of dosages administered per day for each compound may be the same or different. The (a) metformin or a pharmaceutically acceptable salt thereof, the (b) compound of formula (I) or pharmaceutically acceptable salt thereof and optionally (c) the sulfonylurea (preferably glyburide) or pharmaceutically acceptable salt thereof, may be administered via the same or different routes of administration. Examples of suitable methods of administration include, but are not limited to, oral, intravenous (iv), intramuscular (im), subcutaneous (sc), transdermal, and rectal. Compounds may also be administered directly to the nervous system including, but not limited to, intracerebral, intraventricular, intracerebroventricular, intrathecal, intracisternal, intraspinal and / or peri-spinal routes of administration by delivery via intracranial or intravertebral needles and / or catheters with or without pump devices. The (a) metformin or a pharmaceutically acceptable salt thereof, the (b) compound of formula (I) or pharmaceutically acceptable salt thereof and optionally (c) the sulfonylurea (preferably glyburide) or pharmaceutically acceptable salt thereof may be administered according to simultaneous or alternating regimens, at the same or different times during the course of the therapy, concurrently in divided or single forms. One skilled in the art will further recognize that the above discussion related to **“co-therapy”** and **“combination therapy”** will similarly apply to co-therapy or combination therapy for the treatment of a glucose related disorder comprising administration to a subject in need thereof of (a) glyburide, and (b) a compound of formula (I) or pharmaceutically acceptable salt thereof.

To provide a more concise description, some of the quantitative expressions herein are recited as a range from about amount X to about amount Y. It is understood that wherein a range is recited, the range is not limited to the recited upper and lower bounds, but rather includes the full range from about amount X through about amount Y, or any amount or range therein.

To provide a more concise description, some of the quantitative expressions given herein are not qualified with the term **“about”**. It is understood that whether the term “about” is used explicitly or not, every

quantity given herein is meant to refer to the actual given value, and it is also meant to refer to the approximation to such given value that would reasonably be inferred based on the ordinary skill in the art, including approximations due to the experimental and/or measurement conditions for such given value.

5

The present invention further comprises pharmaceutical compositions containing (a) metformin or a pharmaceutically acceptable salt thereof and (b) a compound of formula (I) or pharmaceutically acceptable salt thereof with a pharmaceutically acceptable excipient. Pharmaceutical compositions of the present invention described herein as the active ingredient can be prepared by intimately mixing the (a) metformin or a pharmaceutically acceptable salt thereof and the (b) compound of formula (I) or pharmaceutically acceptable salt thereof with a pharmaceutical excipient according to conventional pharmaceutical compounding techniques.

15 The present invention further comprises pharmaceutical compositions containing (a) glyburide, and (b) a compound of formula (I) or pharmaceutically acceptable salt thereof with a pharmaceutically acceptable excipient. Pharmaceutical compositions of the present invention described herein as the active ingredient can be prepared by intimately mixing the (a) glyburide, and the (b) compound of formula (I) or pharmaceutically acceptable salt thereof with a pharmaceutical excipient according to conventional pharmaceutical compounding techniques.

25 The present invention further comprises pharmaceutical compositions containing (a) metformin or a pharmaceutically acceptable salt thereof, (b) a compound of formula (I) or pharmaceutically acceptable salt thereof, (c) a sulfonylurea or pharmaceutically acceptable salt thereof with a pharmaceutically acceptable excipient. Pharmaceutical compositions of the present invention described herein as the active ingredient can be prepared by intimately mixing the (a) metformin or a pharmaceutically acceptable salt thereof, the (b) compound of formula (I) or pharmaceutically acceptable salt thereof and the (c) sulfonylurea or pharmaceutically acceptable salt thereof with a pharmaceutical excipient according to conventional pharmaceutical compounding techniques.

The pharmaceutically acceptable excipient may take a wide variety of forms depending upon the desired route of administration (e.g., oral, parenteral). Thus for liquid oral preparations such as suspensions, elixirs and solutions, suitable excipients and additives include water, glycols, oils, alcohols, 5 flavoring agents, preservatives, stabilizers, coloring agents and the like; for solid oral preparations, such as powders, capsules and tablets, suitable excipients and additives include diluents, granulating agents, lubricants, binders, disintegrating agents, drug release controlling hydrophilic polymer, drug release controlling hydrophobic polymers, wetting agents and the like. 10 Solid oral preparations may also be coated with substances such as sugars, cellulosic ethers, and acrylic polymers for extended release or may be enteric-coated so as to modulate major site of absorption. For parenteral administration, the excipient will usually consist of sterile water and other ingredients may be added to increase solubility or preservation. Injectable 15 suspensions or solutions may also be prepared utilizing aqueous excipients along with appropriate additives.

To prepare the pharmaceutical compositions of this invention, the compound of formula (I) or pharmaceutically acceptable salt thereof and the (a) metformin or a pharmaceutically acceptable salt thereof and / or the (b) 20 sulfonylurea (preferably glyburide) or pharmaceutically acceptable salt thereof, as the active ingredients, are intimately admixed with a pharmaceutical excipient according to conventional pharmaceutical compounding techniques, which excipient may take a wide variety of forms depending of the form of preparation desired for administration, e.g., oral or parenteral such as 25 intramuscular. In preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed. Thus, for liquid oral preparations, such as for example, suspensions, elixirs and solutions, suitable excipients and additives include water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like; for solid oral preparations such as, 30 for example, powders, capsules, and tablets (including caplets), suitable excipients and additives include diluents, granulating agents, lubricants, binders, disintegrating agents, drug release controlling hydrophilic polymers, drug release controlling or hydrophobic polymers, wetting agents, and the like.

Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical excipients are obviously employed. If desired, tablets may be sugar coated or may be enteric coated by standard techniques. For parenterals, the excipient will usually comprise sterile water, through other ingredients, for example, for purposes such as aiding solubility or for preservation, may be included. Injectable suspensions may also be prepared, in which case appropriate liquid excipients, suspending agents and the like may be employed. The pharmaceutical compositions described herein will contain, per dosage unit, e.g., tablet, capsule, powder, injection, teaspoonful and the like, an amount of the active ingredient(s) necessary to deliver an effective dose as described above. The pharmaceutical compositions herein will contain, per unit dosage unit, e.g., tablet, capsule, powder, injection, suppository, teaspoonful and the like, of from about 0.01 to about 2,000 mg, or any amount or range therein, independently, of each of the (a) metformin or a pharmaceutically acceptable salt thereof, the (b) compound of formula (I) or pharmaceutically acceptable salt thereof, and / or the (c) sulfonylurea (preferably glyburide) or pharmaceutically acceptable salt thereof. The pharmaceutical compositions described herein may be given at a suitably selected therapeutically effective dosage, which may be varied depending upon the requirement of the patients, the severity of the condition being treated and the compound being employed. The use of either daily administration or post-periodic dosing may be employed.

Preferably these pharmaceutical compositions are in unit dosage forms from such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, autoinjector devices or suppositories; for oral parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation. Alternatively, the pharmaceutical composition may be presented in a form suitable for once-weekly or once-monthly administration; for example, an insoluble salt of the active compound(s), such as the decanoate salt, may be adapted to provide a depot preparation for intramuscular injection.

For preparing solid compositions such as tablets, the principal active ingredient(s) are mixed with a pharmaceutical excipient, e.g. conventional

tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid formulation composition containing a mixture of the active ingredient(s). The tablets or pills of the pharmaceutical composition of the present invention can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of material can be used for such enteric layers or coatings, such materials including a number of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.

The liquid forms in which the pharmaceutical compositions of the present invention may be incorporated for administration orally or by injection include, aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions, include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.

Advantageously, the pharmaceutical compositions of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily. Furthermore, the pharmaceutical compositions of the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.

In certain embodiments, for oral administration in the form of a tablet or capsule, the active drug component(s) can be combined with an oral, non-toxic pharmaceutically acceptable inert excipient such as ethanol, glycerol, water and

the like. Moreover, when desired or necessary, suitable binders; lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture. Suitable binders include, without limitation, starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like. Disintegrators include, without limitation, starch, sodium starch glycolate, croscarmellose sodium, crospovidone, methyl cellulose, agar, bentonite, xanthan gum, and the like. The liquid forms in suitably flavored suspending or dispersing agents such as the synthetic and natural gums, for example, tragacanth, acacia, methyl-cellulose and the like. For parenteral administration, sterile suspensions and solutions are desired. Isotonic preparations which generally contain suitable preservatives are employed when intravenous administration is desired.

The pharmaceutical compositions of the present invention may be prepared according to known methods and employing known processes and equipment, as disclosed, for example in Pharmaceutical Sciences, Remington, 17th Ed., pp. 1585-1594 (1985); Chemical Engineers Handbook, Perry, 6th Ed., pp. 21-13 to 21-19 (1984); Journal of Pharmaceutical Sciences, Parrot, Vol. 61, No. 6, pp. 813-829 (1974); and Chemical Engineer, Hixon, pp. 94-103 (1990).

Granules for the pharmaceutical compositions of the present invention may, for example, be prepared by comminution, which produces the desired size of the active ingredient and the desired size of any accompanying pharmaceutically acceptable excipient(s). Suitable means for producing the desired particles include, but are not limited to, granulation, spray drying, sieving, lyophilization, crushing, grinding, jet milling, micronizing and chopping to produce the intended particle size. The process can be performed by size reduction equipment, such as a micropulverizer mill, a fluid energy-grinding mill, a grinding mill, a roller mill, a hammer mill, an attrition mill, a chaser mill, a ball mill, a vibrating ball mill, an impact pulverizer mill, a centrifugal pulverizer, a coarse crusher and a fine crusher. The size of the particle can be ascertained by screening, including a grizzly screen, a flat screen, a vibrating screen, a revolving screen, a shaking screen, an oscillating screen and a reciprocating

screen. The granules are then, for example, pressed according to known methods to yield a tablet.

Granules for the pharmaceutical compositions of the present invention may alternatively be manufactured according to the wet granulation technique.

5 In the wet granulation technique, solid particles are wetted and bound together by a binder solution consisting essentially of a granulation solvent, a binder, and optionally other excipients. The active ingredient (for example, the compound of formula (I-X) or pharmaceutically acceptable salt thereof) may be granulated as solid particles together with or absent other solid excipients, or is
10 partially dissolved in the binder solution. The solid particles can be mixed by means of mechanical agitation (using for example, a low or high shear mixer) or may be fluidized by a gas (as in fluid bed granulation). The granulating fluid is added until a wet blend is produced, which wet mass blend is then forced through a predetermined screen and dried in a fluid bed dryer. The blend is
15 dried for about 18 to about 24 hours at a temperature in the range of from about 24°C to about 35°C in a forced-air oven. The dried granules are then sized, according to known methods. The dried granules are then sized. Next, magnesium stearate, or another suitable lubricant (if desired) and other excipient materials (as appropriate) are added to the granulation, and the
20 granulation is put into milling jar sand mixed on a jar mill for 10 minutes. For the preparation of tablets, the resulting composition is pressed into a layer, for example, in a Manesty® press or a Korsch LCT press. In an example, the speed of the press is set at 15 rpm and the maximum load set at about 4 tons.

Alternatively, the active ingredient and excipient(s) may be blended as
25 powdered ingredients in a fluid bed granulator. After the powdered ingredients are dry blended in the granulator, a granulating fluid, for example, polyvinylpyrrolidone in water, is sprayed onto the powders. The resulting agglomerated materials are then dried in the granulator. This process granulates all the ingredients present therein while adding the granulating fluid.
30 After the granules are dried, a lubricant, such as stearic acid or magnesium stearate, is mixed into the granulation using a blender e.g., V-blender or tote blender. The granules are then pressed and coated in the manner described above.

Exemplary solvents suitable for manufacturing the pharmaceutical composition components comprise aqueous or inert organic solvents that do not adversely harm the materials used in the system. The solvents broadly include members selected from the group consisting of aqueous solvents, 5 alcohols, ketones, esters, ethers, aliphatic hydrocarbons, halogenated solvents, cycloaliphatics, aromatics, heterocyclic solvents and mixtures thereof. Typical solvents include acetone, diacetone alcohol, methanol, ethanol, isopropyl alcohol, butyl alcohol, methyl acetate, ethylacetate, isopropyl acetate, n-butyl acetate, methyl isobutyl ketone, methyl propyl ketone, nhexane, n-heptane, 10 ethylene glycol monoethyl ether, ethylene glycol monoethyl acetate, methylene dichloride, ethylene dichloride, propylene dichloride, carbon tetrachloridenitroethane, nitropropane tetrachloroethane, ethyl ether, isopropyl ether, cyclohexane, cyclooctane, benzene, toluene, naphtha, 1,4-dioxane, tetrahydrofuran, diglyme, water, aqueous solvents containing inorganic salts 15 such as sodium chloride, calcium chloride, and the like, and mixtures thereof such as acetone and water, acetone and methanol, acetone and ethyl alcohol, methylene dichloride and methanol, and ethylene dichloride and methanol.

Where desired, pan coating may be used to provide a completed dosage 20 form. In the pan coating system, the coating composition is deposited by successive spraying onto the compressed tablet, accompanied by tumbling in a rotating pan. A pan coater is commonly used because of its availability at commercial scale. Other techniques can be used for coating the tablet. Once coated, the tablet is dried in, for example, the same equipment of in a forced-air 25 oven or in a temperature and humidity controlled oven to free the dosage form of solvent(s) used in the manufacturing. Drying conditions are conventionally chosen on the basis of available equipment, ambient conditions, solvents, coatings, coating thickness, and the like.

Other coating techniques can also be employed. For example, one 30 alternative technique uses an air-suspension procedure. This procedure consists of suspending and tumbling the tablet in a current of air, until a coating is applied. The air-suspension procedure is described in, for example, U.S. Patent No. 2,799,241; in J. Am. Pharm. Assoc., Vol. 48, pp. 451-459 (1959);

and, *ibid.*, Vol. 49, pp. 82-84 (1960). The tablet also can be coated with a Wurster® air-suspension coater using, for example, methylene dichloride methanol as a co-solvent for the coating material. An Aeromatic® air-suspension coater can be used employing a co-solvent.

5 The co-therapy comprising (a) metformin or a pharmaceutically acceptable salt thereof and (b) a compound of formula (I) or pharmaceutically acceptable salt thereof, of the present invention may be administered in any of the foregoing compositions and according to dosage regimens established in the art whenever treatment of a glucose related disorder is required.

10 The co-therapy comprising (a) glyburide, and (b) a compound of formula (I) or pharmaceutically acceptable salt thereof, of the present invention may be administered in any of the foregoing compositions and according to dosage regimens established in the art whenever treatment of a glucose related disorder is required.

15 The co-therapy comprising (a) metformin or a pharmaceutically acceptable salt thereof, (b) a compound of formula (I) or pharmaceutically acceptable salt thereof, and (c) a sulfonylurea (preferably glyburide) or pharmaceutically acceptable salt thereof, of the present invention may be administered in any of the foregoing compositions and according to dosage
20 regimens established in the art whenever treatment of a glucose related disorder is required.

 In an embodiment, for oral administration, the compositions are preferably provided in the form of tablets containing, 50, 100, 150, 200, 250, 500, 750, 850, 1000, 1500 or 2000 milligrams of the metformin or pharmaceutically acceptable
25 salt thereof (preferably metformin hydrochloride); and further containing 1, 5, 10, 25, 50, 100, 150, 200, 250, 300 or 500 milligrams of the compound of formula (I) or pharmaceutically acceptable salt thereof. In another embodiment, for oral administration, the compositions are preferably provided in the form of tablets containing, 1.0, 2.5, 5.0, 7.5, 10.0, 12.5, 15 or 20 milligrams, of the glyburide; and
30 further containing 1, 5, 10, 25, 50, 100, 150, 200, 250, 300 or 500 milligrams of the compound of formula (I) or pharmaceutically acceptable salt thereof. In another embodiment, for oral administration, the compositions are preferably provided in the form of tablets containing, 50, 100, 150, 200, 250, 500, 750, 850,

1000, 1500 or 2000 milligrams of the metformin or pharmaceutically acceptable salt thereof (preferably metformin hydrochloride); further containing 1, 5, 10, 25, 50, 100, 150, 200, 250, 300 or 500 milligrams of the compound of formula (I) or pharmaceutically acceptable salt thereof (preferably a compound of formula (I-X) or pharmaceutically acceptable salt thereof or a compound of formula (I-Y) or pharmaceutically acceptable salt thereof), and further containing 1.0, 2.5, 5.0, 7.5, 10.0, 12.5, 15, 20, 25, 50, 100, 250, 500 or 1000 milligrams, of the sulfonylurea or pharmaceutically acceptable salt thereof.

10 Preferably, the metformin or pharmaceutically acceptable salt thereof (more preferably, metformin hydrochloride) is administered at a dosage level of from about 0.01 mg/kg to about 200 mg/kg of body weight per day, or from about 0.5 mg/kg to about 50 mg/kg of body weight per day, or any amount or range therein. Preferably, the range is from about 1.0 to about 50.0 mg/kg of body weight per day, or any amount or range therein, more preferably, from about 5 mg/kg to about 30 mg/kg, or any amount or range therein, more preferably, from about 5 to about 20 mg/kg of body weight per day, or any amount or range therein. In an embodiment, an effective amount of the metformin or pharmaceutically acceptable salt thereof is supplied at a dosage level of 250 mg, 500 mg, 750 mg, 1000 mg or 2000 mg, or any amount or range therein.

20 Preferably, the glyburide is administered at a dosage level of from about 0.01 mg/kg to about 0.5 mg/kg of body weight per day, or from about 0.01 mg/kg to about 0.3 mg/kg of body weight per day, or any amount or range therein. In an embodiment, an effective amount of the glyburide is supplied at a dosage level of 1.0 mg, 2.5 mg, 5.0 mg, 7.5 mg, 10.0 mg, 12.5 mg, 15 mg, or 20 mg, or any amount or range therein.

30 Preferably, the compound of formula (I) or pharmaceutically acceptable salt thereof is administered at a dosage level of from about 0.01 mg/kg to about 500 mg/kg of body weight per day, or 0.01 mg/kg to about 200 mg/kg of body weight per day, or any amount or range therein. Preferably, the range is from about 0.01 to about 50 mg/kg of body weight per day, or any amount or range therein, more preferably, from about 0.05 mg/kg to about 10 mg/kg, or any amount or range therein, more preferably, from about 1 to about 5 mg/kg of body

weight per day, or any amount or range therein. In an embodiment, an effective amount of the compound of formula (I) or pharmaceutically acceptable salt thereof is supplied at a dosage level of 10 mg, 25 mg, 50 mg, 100 mg, 150 mg or 300 mg, or any amount or range therein. Preferably, the sulfonylurea or
5 pharmaceutically acceptable salt thereof is administered at a dosage level of from about 0.01 mg/kg to about 200 mg/kg of body weight per day, or any amount or range therein. Preferably, the range is from about 0.01 to about 50 mg/kg of body weight per day. In an embodiment, an effective amount of the sulfonylurea or pharmaceutically acceptable salt thereof is supplied at a dosage level of 1.0 mg,
10 2.5 mg, 5.0 mg, 10 mg, 25 mg, 50 mg, 100 mg, 150 mg, 250 mg, 500 mg, 100 mg, or any amount or range therein. The co-therapy of the present invention may be administered on a regimen of 1 to 4 times per day.

Optimal dosages to be administered may be readily determined by those skilled in the art, and will vary with for example, the mode of administration, the
15 strength of the preparation, the mode of administration, and the advancement of the disease condition. In addition, factors associated with the particular patient being treated, including patient age, weight, diet and time of administration, will result in the need to adjust dosages.

One skilled in the art will recognize that, both *in vivo* and *in vitro* trials
20 using suitable, known and generally accepted cell and / or animal models are predictive of the ability of a test compound or co-therapy to treat or prevent a given disorder. One skilled in the art will further recognize that human clinical trials including first-in-human, dose ranging and efficacy trials, in healthy patients and / or those suffering from a given disorder, may be completed
25 according to methods well known in the clinical and medical arts.

The following Examples are set forth to aid in the understanding of the invention, and are not intended and should not be construed to limit in any way the invention set forth in the claims which follow thereafter.

An ability and unexpected synergistic effect of co-therapy of metformin
30 and the compound of formula (I) to treat glucose related disorders, for example, Type 2 diabetes mellitus and Syndrome X, is based on the following animal study.

Example 1: *in vivo* Mouse Study

Male C57BL/6 mice (total of 100 mice) were fed with a high fat diet from the age of 3 weeks to 6 weeks (total 3 weeks). After 3 weeks on a high fat diet, all the mice received a single-dose ip injection of Steptozotocin (STZ) (100
5 mg/kg, in 0.05 mol/L citric acid, pH4.5, 10mg/ml). All the mice were then kept on a high fat diet for another 3 weeks. Those mice with fasted blood glucose levels > 7 mM and <15 mM were selected for the study.

At the start of the pre-dose period, each mouse was assigned a predose number, which was indicated on its cage card. After assignment to dosage
10 groups, each mouse was assigned a unique study identification number (which will be indicated on its cage card) and identified by permanent marker on its tail. Mice were housed 5 mice per cage in stainless steel cages. The study room was maintained on a 12-hour light/dark cycle (light/dark cycle may be interrupted for study-related activities), within a temperature range of 64°F to
15 79°F, and a relative humidity range of 30% to 70%. The temperature and humidity ranges will be monitored by a hygrothermograph. Mice were fed *ad libitum* (except where noted) with high-fat diet prepared in Southern University. Water was provided *ad libitum* by water bottles.

Study Design:

20 The quarantine period was 5 days. The test compound or vehicle was administered orally by gavage. The dosage levels were chosen to represent a range of exposures with pharmacology effects.

Mice were selected on the basis of pre-dose evaluations at day –1 and randomly assigned to groups using a computer-generated randomization
25 method based on body weight and fasted blood glucose levels. The mean values of body weight and fasted blood glucose level of each group were similar (within < 5% variation).

The mice were randomly divided into six testing group of 10 mice per group. Each group was treated for 3 weeks, via oral administration, with one of
30 the following regimens: (a) vehicle; (b) the compound of formula (I-Y) at 1 mg/kg; (c) the compound of formula (I-Y) at 10 mg/kg; (d) metformin at 500 mg/kg; (e) a combination of the compound of formula (I-Y) at 1 mg/kg and

metformin at 500 mg/kg; and (f) a combination of the compound of formula (I-Y) at 10 mg/kg and metformin at 500 mg/kg.

On Day 1 (the first day of dosing), dosing at all dose levels was initiated. All groups were then dosed for 20 additional days. The following

5 pharmacological parameters were measured during and at the end of this study: (a) fed blood glucose were measured at day 1, 7, 14, and 21 day before dosing; (b) body weight of each mouse was measured at day –1 (for grouping), 1, 7, 14, and 21, after blood glucose measurement; and (c) 24 hr food intake (average of 5 mice per cage) was measured at day 1, 7, 14, and 20.

10 On day 18 of treatment, mice were fasted overnight (5 pm – 8 am), after a change to a new cage. The following morning, a basal fasted blood glucose level was determined. Then, glucose solution (20% glucose, 2 g/kg body weight, 1 ml/100 g of body weight, prepared freshly before oral glucose tolerance test, (OGTT) was administrated via oral gavage. Blood glucose
15 levels were measured using tail blood at 30, 60, and 120 min after glucose challenge. Food was replaced after the last time point of blood glucose measurement.

The pharmacological significance of any findings was determined based on statistical analysis and historical control data. Statistical analyses were
20 performed utilizing GraphPadPRISM.

The compound of formula (I-Y) alone and in combination with metformin was tested according to the procedure as described above, with results as listed in Table 1, below.

Table 1: *in vivo* Mouse Assay Results

Treatment	Fed Glucose (mg/dL)	Fasted Glucose (mg/dL)	Blood Glucose AUC during OGTT (mg/dL*2h)
Vehicle	421.5 ± 25.9	87.0 ± 6.1	36951 ± 2592
Cmpd (I-Y) (1 mg/kg)	360.7 ± 15.7	77.8 ± 4.9	31562 ± 1447
Cmpd (I-Y) (10 mg/kg)	290.5 ± 24.8	66.9 ± 3.1	25209 ± 894
Metformin (500 mg/kg)	345.4 ± 28.4	74.7 ± 3.8	34023 ± 1618

Cmpd (I-Y) (1 mg/kg) + Metformin (500 mg/kg)	290.0 ± 15.4	75.7 ± 11.3	28934 ± 1464
Cmpd (I-Y) (10 mg/kg) + Metformin (500 mg/kg)	223.7 ± 12.2	54.1 ± 4.1	19395 ± 584
Treatment	Fed Glucose (% relative to the Vehicle)	Fasted Glucose (% relative to the Vehicle)	Blood Glucose AUC during OGTT (% relative to the Vehicle)
Vehicle	100% ± 6%	100.0% ± 7.0%	100% ± 7%
Cmpd (I-Y) (1 mg/kg)	86% ± 4%	89.4% ± 5.7%	85% ± 4%
Cmpd (I-Y) (10 mg/kg)	69% ± 6%	76.9% ± 3.6%	68% ± 2%
Metformin (500 mg/kg)	82% ± 7%	85.9% ± 4.4%	92% ± 4%
Cmpd (I-Y) (1 mg/kg) + Metformin (500 mg/kg)	69% ± 4%	87.0% ± 13.0%	78% ± 4%
Cmpd (I-Y) (10 mg/kg) + Metformin (500 mg/kg)	53% ± 3%	62.2% ± 4.7%	52% ± 2%

Example 2: *in vivo* Mouse Study

- Male ob/ob mice (8-week old, ~50g) were housed 2 mice per cage in a temperature-controlled room with 12-hour light/dark cycle. The mice were
- 5 allowed *ad libitum* access to water and chow (commercially supplied diet). Mice were grouped into 6 test groups based on their body weight and fed blood glucose levels, as noted in Table 2, below.

Table 2: Mouse Treatment groups

Group	Treatment
1	Vehicle (0.5% Methocel) 1 ml/100 g, P.O.
2	Compound of formula (I-X) @ 1.0 mpk: 1 ml/100 g, P.O.
3	Compound of formula (I-X) @ 10.0 mpk: 1 ml/100 g, P.O.
4	Metformin HCl: 250 mpk: 1 ml/100 g, P.O.
5	Compound of formula (I-X) @ 1 mpk Metformin HCl: 250 mpk, 1 ml/100 g, P.O.

6	Compound of formula (I-X) @ 10 mpk Metformin HCl: 250 mpk, 1 ml/100 g, P.O.
---	--

Study Design:

On the first morning, the mice were grouped as noted above and fed glucose. The mice were then dosed with vehicle or test compound(s) via gavage at 4:00 pm each day for 22 days q.d. The compound of formula (I-X) was dosed at 1mg/kg or 10 mg/kg (as noted in the result table below) with or without treatment with metformin HCl at a dosage of 250 mg/kg.

Body weight, food intake and fed blood glucose levels were measured weekly. An oral glucose tolerance test (OGTT) was conducted on the mice on day 18, after overnight fasting. Glucose concentrations of 0.5 g/kg BW, and blood glucose levels of OGTT were measured using a Glucometer at t_0 (before glucose dosing), t_{30} , t_{60} , and t_{120} corresponding to 30, 60 and 120 minutes following administration. The administered glucose solution was prepared at 0.5 g/kg using 12.5% glucose, 1 ml/250 g BW.

Following completion of the study, final body weight and blood glucose level of were collected and the mice in each group was sacrificed to collect blood for biochemistry analysis, including fed blood glucose levels, fasted blood glucose levels, blood glucose levels during OGTT, plasma insulin and body weight change.

The compound of formula (I-X) alone and in combination with metformin was tested according to the procedure as described above, with results as listed in Table 3, below.

Table 3: *in vivo* ob/ob Mouse Assay Results

Treatment	Fed Glucose (mg/dL)	Fasted Glucose (mg/dL)	Blood Glucose AUC during OGTT (mg/dL*2h)
Vehicle	345±19	174±11	100±5
Cmpd (I-X) (1 mg/kg)	312±34	159±12	80±4
Cmpd (I-X) (10 mg/kg)	254±22	86±4	48±3

Metformin HCl (250 mg/kg)	371±35	166±16	91±9
Cmpd (I-X) (1 mg/kg) + Metformin HCl (250 mg/kg)	285±23	153±12	77±7
Cmpd (I-X) (10 mg/kg) + Metformin HCl (250 mg/kg)	216±10	110±11	56±3
Treatment	Plasma Insulin (ng/dL)		Body Weight (g)
Vehicle	38.6±3.3		54±0.8
Cmpd (I-X) (1 mg/kg)	46.3±3.5		53±0.8
Cmpd (I-X) (10 mg/kg)	44.0±3.6		54±0.8
Metformin HCl (250 mg/kg)	48.4±2.0		52±0.9
Cmpd (I-X) (1 mg/kg) + Metformin HCl (250 mg/kg)	52.6±1.2		53±0.8
Cmpd (I-X) (10 mg/kg) + Metformin HCl (250 mg/kg)	53.1±1.4		51±1.0

The results in Table 3 above indicate that the compound of formula (I-X) at 10 mg/kg significantly reduced blood glucose levels and improved glucose excursion during OGTT. The results further showed no additive or synergistic effect in mice treated with the combination of metformin and the compound of formula (I-X). Additionally, the results show that metformin at 250 mg/kg did not have an effect on blood glucose control, suggesting that the ob/ob mouse is not a suitable animal model to demonstrate the activity of metformin (given the mechanism by which metformin acts on glucose levels). The lack of an additive and / or synergistic effect for the combination of the compound of formula (I-X) and metformin, is therefore believed to be a result of this model's limitation in demonstrating known anti-diabetic activity.

Example 3

15 Pharmaceutical Composition – Combination of Metformin Hydrochloride and the Compound of Formula (I-X)

A pharmaceutical composition comprising metformin hydrochloride and the compound of formula (I-X) was prepared as follows, with Table 4, below listing the components in the formulation. Metformin HCl was purchased as commercially available Drug Substance (DS) from Solmag S.P.A Mulazzano
5 (Via Della Vittoria 89, 26837 Cassino d' Alberi, Mulazzano, Italy).

Table 4: Combination Tablet Formulation

Description	Function	mg/tablet	%w/w	Quantity/Batch (g)
Intragranular Additions				
Compound of Formula (I-X)	Drug Substance -1	200.0	14.69	132.2
Metformin HCl	Drug Substance -2	1000.0	73.46	660.8
Microcrystalline Cellulose	Filler	59.2	4.35	39.1
Povidone (K29/32) ¹	Binder	54.50	4.00	36.0
Croscarmellose sodium	Disintegrant	40.80	3.00	27.3
Water ²	NA	N/A		
Extragranular Additions				
Magnesium Stearate, 2257	Lubricant	6.8	0.50	4.5
Totals	100.0	1361.3	100.0	899.6
¹ Added as 6% solids in solution				
² Not in final formulation				

Metformin hydrochloride, the compound of formula (I-X), microcrystalline cellulose (MCC) and croscarmellose sodium were screened and blended in
10 bohle bin blender (L.B Bohle Maschinen + Verfhren GmbH, Ennigerloh, Germany). The resulting materials were fluidized in a Glatt Fluid bed processor (Glatt Air Techniques, Ramsay, NJ) with 1.0 mm nozzle and aircap setting of 2. The binder (Povidone K29/32), as a 6% w/w solids solution in water, was then
15 sprayed onto the resulting granules. The moisture level and granulation growth were monitored during the process, with samples taken every 10 minutes of the process. Moisture balance was used to determine loss on drying (LOD).

The dried granulation was then lubricated with screened magnesium stearate in a bohle bin blender. The final blend was compressed into tablets on

a rotary press, Fette 1200i (Fette GmbH, Schwarzenbek, Germany) equipped with 0.830" X 0.4095" D-tooling and low quantity feeder. The Batch was compressed using two stations to the target tablet weight. Five different compression profiles were used to produce tablets.

5 For the five compression profile sub-batches, tablet weight variation was less than 1% and friability was less than 0.5%. Tablet hardness increased with compression from 16 kp at 14.6 KN compression to 25 kp at 31.3 KN compression, and corresponding tablet thickness decreased from 7.32 ± 0.3 mm at 14.6 KN to 6.84 ± 0.3 mm at 31.3 KN. Disintegration time increased with
10 compression from about 4:50 min at 14.6 KN compression to about 9:40 min at 31.3 KN. A measure of the dissolution rate showed that at 30 minutes, between about 85% to about 93% of the compound of formula (I-X) was released, and between about 94% and about 99% of the metformin hydrochloride was released.


15

 While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, it will be understood that the practice of the invention encompasses all of the usual variations, adaptations and/or modifications as come within the scope of the
20 following claims and their equivalents.

What is claimed is:

1. A method for treating a glucose related disorder comprising administering to a subject in need thereof a therapeutically effective amount of co-therapy comprising

- 5 (a) metformin or a pharmaceutically acceptable salt thereof; and
(b) a compound of formula (I)



wherein Ring A and Ring B are one of the followings:

- (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; or
- (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, or an optionally substituted unsaturated fused heterobicyclic ring wherein Y is linked to the heterocyclic ring of the fused heterobicyclic ring; or
- (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, wherein the sugar moiety X-(sugar) and the moiety -Y-(Ring B) are both on the same heterocyclic ring of the fused heterobicyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring;

X is a carbon atom or a nitrogen atom; and


Y is $-(CH_2)_n-$ (wherein n is 1 or 2);

- 25 or a pharmaceutically acceptable salt thereof,

wherein the glucose related disorder is selected from the group consisting of diabetes mellitus, diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, delayed wound healing, insulin resistance, hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids, elevated blood levels of glucose, hyperlipidemia, obesity, hypertriglyceridemia, Syndrome X, diabetic complications, atherosclerosis and hypertension.

2. A method for treating a glucose related disorder comprising administering to a subject in need thereof a therapeutically effective amount of co-therapy comprising

- 5 (a) metformin or a pharmaceutically acceptable salt thereof; and
(b) a compound of formula (I)



wherein Ring A and Ring B are one of the followings:

- (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; or
- (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, or an optionally substituted unsaturated fused heterobicyclic ring wherein Y is linked to the heterocyclic ring of the fused heterobicyclic ring; or
- (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, wherein the sugar moiety X-(sugar) and the moiety -Y-(Ring B) are both on the same heterocyclic ring of the fused heterobicyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring;

X is a carbon atom or a nitrogen atom; and


Y is $-(CH_2)_n-$ (wherein n is 1 or 2);

- 25 or a pharmaceutically acceptable salt thereof,

wherein the glucose related disorder is type 2 diabetes mellitus.

3. A method for treating a glucose related disorder comprising administering to a subject in need thereof a therapeutically effective amount of co-therapy comprising

- 5 (a) metformin or a pharmaceutically acceptable salt thereof; and
(b) a compound of formula (I)



wherein Ring A and Ring B are one of the followings:

- (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; or
- (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, or an optionally substituted unsaturated fused heterobicyclic ring wherein Y is linked to the heterocyclic ring of the fused heterobicyclic ring; or
- (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, wherein the sugar moiety X-(sugar) and the moiety -Y-(Ring B) are both on the same heterocyclic ring of the fused heterobicyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring;


X is a carbon atom or a nitrogen atom; and

Y is $-(CH_2)_n-$ (wherein n is 1 or 2);

- 25 or a pharmaceutically acceptable salt thereof,

wherein the compound of formula (I) is a

compound of formula (I-X)




or pharmaceutically acceptable salt thereof.

4. A method as in Claim 3, wherein the compound of formula (I-X) is a crystalline hemihydrate.

5. A method for treating a glucose related disorder comprising administering to a subject in need thereof a therapeutically effective amount of co-therapy comprising

- 5 (a) metformin or a pharmaceutically acceptable salt thereof; and
(b) a compound of formula (I)



wherein Ring A and Ring B are one of the followings:

- (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; or
- (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, or an optionally substituted unsaturated fused heterobicyclic ring wherein Y is linked to the heterocyclic ring of the fused heterobicyclic ring; or
- (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, wherein the sugar moiety X-(sugar) and the moiety -Y-(Ring B) are both on the same heterocyclic ring of the fused heterobicyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring;

X is a carbon atom or a nitrogen atom; and


Y is $-(CH_2)_n-$ (wherein n is 1 or 2);

- 25 or a pharmaceutically acceptable salt thereof,

wherein the metformin or pharmaceutically acceptable salt thereof is metformin hydrochloride; and wherein the metformin hydrochloride is administered at a dosage of between about 100 mg and about 2000 mg.

6. A method for treating a glucose related disorder comprising administering to a subject in need thereof a therapeutically effective amount of co-therapy comprising

- 5 (a) metformin or a pharmaceutically acceptable salt thereof; and
(b) a compound of formula (I)



wherein Ring A and Ring B are one of the followings:

- (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; or
- (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, or an optionally substituted unsaturated fused heterobicyclic ring wherein Y is linked to the heterocyclic ring of the fused heterobicyclic ring; or
- (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, wherein the sugar moiety X-(sugar) and the moiety -Y-(Ring B) are both on the same heterocyclic ring of the fused heterobicyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring;

X is a carbon atom or a nitrogen atom; and

Y is $-(CH_2)_n-$ (wherein n is 1 or 2);


- 25 or a pharmaceutically acceptable salt thereof,

wherein the compound of formula (I) or

pharmaceutically acceptable salt thereof is administered at a dosage in the range of from about 50 mg to about 500 mg.

7. A method for treating a glucose related disorder comprising administering to a subject in need thereof a therapeutically effective amount of co-therapy comprising

- 5 (a) metformin hydrochloride; and
(b) a compound of formula (I-X)



(I-X)

or pharmaceutically acceptable salt thereof.


- 10 8. A method as in Claim 7, wherein the glucose related disorder is selected from the group consisting of diabetes mellitus, diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, delayed wound healing, insulin resistance, hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids, elevated blood levels of glucose, hyperlipidemia, obesity, hypertriglyceridemia,
15 Syndrome X, diabetic complications, atherosclerosis and hypertension.

9. A method as in Claim 8, wherein the glucose related disorder is type 2 diabetes mellitus.

- 20 10. A method as in Claim 7, wherein the metformin hydrochloride is administered at a dosage of between about 100 mg and about 2000 mg.

11. A method as in Claim 7, wherein the compound of formula (I-X) or pharmaceutically acceptable salt thereof is administered at a dosage in the
25 range of from about 50 mg to about 500 mg.

12. A pharmaceutical composition comprising
 (a) metformin hydrochloride;
 (b) a compound of formula (I-X)



5


or a pharmaceutically acceptable salt thereof; and
 (c) a pharmaceutically acceptable excipient.

13. A pharmaceutical compositions as in Claim 12, wherein the metformin
 10 hydrochloride is present in an amount in the range of from about 100 mg to
 about 2000 mg; and wherein the compound of formula (I-X) or pharmaceutically
 acceptable salt thereof is present in an amount in the range of from about 50
 mg to about 500 mg.

- 15 14. A pharmaceutical composition as in Claim 12, wherein the metformin
 hydrochloride is present in an amount of about 250 mg, about 500 mg, about
 750 mg, about 850 mg, or about 1000 mg; and wherein the compound of
 formula (I-X) or pharmaceutically acceptable salt thereof is present in an
 amount of about 100 mg, about 150 mg or about 300 mg.

20

15. A pharmaceutical composition comprising
 (a) metformin or a pharmaceutically acceptable salt thereof;
 (b) a compound of formula (I-X)



or pharmaceutically acceptable salt thereof;

(c) a sulfonylurea or pharmaceutically acceptable salt thereof; and

(d) a pharmaceutically acceptable excipient.

5

16. A pharmaceutical composition as in Claim 15, wherein the sulfonylurea is selected from the group consisting of chlorpropamide, tolazamide, tolbutamide, glyburide, glipizide and glimepiride.

10 17. A pharmaceutical composition as in Claim 15, wherein the metformin or pharmaceutically acceptable salt thereof is metformin hydrochloride; and wherein the sulfonylurea is glyburide.

15 18. A pharmaceutical composition as in Claim 15, wherein the metformin hydrochloride is present in an amount in the range of from about 100 mg to about 2000 mg; the compound of formula (I-X) or pharmaceutically acceptable salt thereof is present in an amount in the range of from about 50 mg to about 500 mg; and the glyburide is present in an amount in the range of from about 2.5 mg to about 20 mg.

20